CURRICULUM VITAE
CURRICULUM VITAE
NAME STEPHEN P. HUNGER, M.D.
SOCIAL SECURITY NUMBER Available upon request
CITIZENSHIP United States
DATE AND PLACE OF BIRTH Available upon request
MARITAL STATUS Married with two children
PROFESSIONAL POSITIONS Professor, Department of Pediatrics
University of Colorado School of Medicine
Aurora, CO
Ergen Family Chair in Pediatric Cancer
Director, Center for Cancer and Blood Disorders
Chief, Section of Pediatric Hematology/ Oncology/Bone Marrow Transplantation
Children's Hospital Colorado, Aurora CO
WORK ADDRESS Center for Cancer and Blood Disorders
Children's Hospital Colorado
13123 East 16th Avenue, Box B115
Aurora, CO 80045
HOME ADDRESS Available upon request
ACADEMIC DEGREES
B.S. 1981 Massachusetts Institute of Technology; Cambridge, MA (Applied Biology)
M.D. 1985 University of Connecticut School of Medicine; Farmington, CT
POST-GRADUATE TRAINING AND FELLOWSHIP APPOINTMENTS
1985-1986 Intern, Pediatrics, The Johns Hopkins Hospital; Baltimore, MD
1986-1987 Assistant Resident, Pediatrics, The Johns Hopkins Hospital; Baltimore, MD
1988. Senior Assistant Resident, Pediatrics, Johns Hopkins Hospital; Baltimore, MD
1991. Postdoctoral Fellow, Pediatric Hematology-Oncology, Stanford University School of Medicine; Stanford, CA
1991-1994 Postdoctoral Scholar (Research), Department of Pathology (Laboratory of Dr. Michael Cleary), Stanford University School of Medicine; Stanford, CA
FACULTY APPOINTMENTS
1994-2000: Assistant Professor of Pediatrics, University of Colorado Health Sciences Center; Denver, CO
2000-2001: Associate Professor of Pediatrics, University of Colorado Health Sciences Center; Denver, CO
2001-2004: Associate Professor of Pediatrics, University of Florida College of Medicine; Gainesville, FL
2001-: STOP! Children’s Cancer Endowed Chair, University of Florida College of Medicine; Gainesville, FL
2001-2006 Joint Associate Professor, Department of Molecular Genetics and Microbiology, University of Florida College of Medicine; Gainesville FL
2004-2006: Associate Professor of Pediatrics (with tenure), University of Florida College of Medicine; Gainesville, FL
2004-2006: Joint Associate Professor (with tenure), Department of Molecular Genetics and Microbiology, University of Florida College of Medicine; Gainesville FL
2006-2007: Professor of Pediatrics (with tenure), University of Florida College of Medicine; Gainesville, FL
2006-2007: Joint Professor (with tenure), Department of Molecular Genetics and Microbiology, University of Florida College of Medicine; Gainesville FL
2007-present Professor (with tenure), Department of Pediatrics, University of Colorado School of Medicine; Aurora, CO
MAJOR ADMINISTRATIVE POSTIONS
2001-2007: Chief, Division of Pediatric Hematology/Oncology, University of Florida College of Medicine; Gainesville, FL
2001-2007: Medical Director, Pediatric Hematology/Oncology Outpatient Clinic, Shands Hospital at the University of Florida; Gainesville, FL
2001-2007: Medical Director, Pediatric Hematology/Oncology Inpatient Service, Shands Hospital at the University of Florida; Gainesville, FL
2001-2007: Children’s Medical Services (State of Florida) Pediatric Hematology/Oncology Program Director, Shands Hospital at the University of Florida; Gainesville, FL
2003-2006: Director, Pediatric Hematology/Oncology Subspecialty Resident (Fellow) Training Program, University of Florida College of Medicine; Gainesville, FL
2003-2007: Director, Pediatric Bone Marrow Transplant Service, Shands Hospital at the University of Florida; Gainesville, FL
2007-present: Chief, Section of Pediatric Hematology/ Oncology/Bone Marrow Transplantation, Department of Pediatrics, University of Colorado School of Medicine; Aurora, CO
2007-present: Director, Center for Cancer and Blood Disorders, Children's Hospital Colorado, Aurora CO
2008-2010 Associate Director, University of Colorado Cancer Center
2010-present Clinical Director, Hematology; Center for Cancer and Blood Disorders, Children's Hospital Colorado, Aurora CO
2011- Staff Investigator (Pediatric Oncology), University of Colorado Cancer Center
2011- Head (Acting) Biology and Treatment of Childhood Cancer Research Emphasis Area, The Children’s Hospital
MEDICAL LICENSURE
1987-1988 Maryland
1988-1996 California
1994-present Colorado
2002-2008 Florida
CERTIFICATION
Diplomate, National Board of Medical Examiners, 1986
Diplomate, American Board of Pediatrics, 1989; re-certified 1999 - 2006
Diplomate, Sub-board of Pediatric Hematology-Oncology, American Board of Pediatrics, 1992; re-certified 1998 and 2006, expires 2013
HONORS/AWARDS
1981. National Merit Scholar
1977. Undergraduate Research Opportunities Award, Massachusetts Institute of Technology
1982 Linda Ives Memorial Fund Award for Research in Pediatrics, University of Connecticut School of Medicine
1989-1990 American Cancer Society Clinical Oncology Fellowship Award
1991-1992 American Cancer Society Physician's Research Training Award
1992-1994 Individual National Research Service Award, National Cancer Institute
1997. BLOOD/American Society of Hematology (ASH) Scholar Award
1997-1999 Professional Development Award, The Children’s Hospital Research Institute, Denver, CO
2001. Leukemia Society of America Translational Research Awardee
2001-2007 STOP! Children’s Cancer Endowed Chair in Pediatric Oncology
5/7-5/8/2002 Daniel Burton Visiting Lecturer in Leukemia Research, Hospital for Sick Children, Toronto, Ontario, Canada
2002-present Listed in The Best Doctors In America (Woodward/White)
2003-present Member, Society for Pediatric Research
2004-present Listed in Guide to America’s Top Physicians (Consumer’s Research Council)
2007-present Ergen Family Chair in Pediatric Cancer
2009-present Listed in Guide to America’s Top Oncologists (Consumer’s Research Council)
2009 SIOP Award for Basic Science Abstract
6/14/2010 Visiting Professor, Children’s Mercy Hospital, Kansas City, MO
4/21/2011 Visiting Professor, Memorial Sloan Kettering Cancer Center, New York City, NY
5/2-3/2011 Visiting Professor, Children’s Hospital of Philadelphia, Philadelphia, PA
2011- Listed in Cambridge Who’s Who Executive and Professional Registry
PROFESSIONAL SOCIETY MEMBERSHIPS
American Association for the Advancement of Science
American Society of Clinical Oncology
American Society of Hematology
American Society of Microbiology
American Society of Pediatric Hematology-Oncology
Children’s Oncology Group
International Society of Paediatric Oncology (member #860)
Society for Pediatric Research
CHILDREN’S CANCER GROUP AND CHILDREN’S ONCOLOGY GROUP ACTIVITIES
1994-98 Member, CCG Biology Research Committee
1996-2000 Member, CCG Young Investigator Committee
2000. Chairman, CCG Young Investigator Committee
2000. Member, CCG Voting Body
1998-2001 Principal Investigator, CCG B9805: The Incidence and Prognostic Significance of p16/p15 Gene Abnormalities in Children with Relapsed ALL Treated in CCG 1941
1998-present Member, CCG B9801 Study Committee: Collection of Research specimens for Studying Apoptosis and the role of Oncoproteins in the Induction of Apoptosis in Leukemia Blast Cells
1998-present Member, CCG B969 Study Committee: Molecular Genetic and Clinical Outcome in High Risk Pediatric ALL Patients
1999-2000 Member, Biology and Translational Research Program, CCG
1999-2001 Co-Chairman, COG Young Investigator Committee
1999-present Member, CCG 1991 Study Committee: Escalating intravenous vs. oral methotrexate and single vs. double delayed intensification therapy for standard risk acute lymphoblastic leukemia
1999-present Member, Biology and Translational Research Committee, COG
1999-2008 Member, COG ALL Biology Committee; Co-Chair of Reference Laboratory Subcommittee
2000-present Member, COG ALL Disease Committee
2000-2008 Chairman, COG ALL Cell Bank Committee
2001-2003 Member, COG Membership Committee
2001-2003 Chair, COG Laboratory Science Discipline
2001-2007 Principal Investigator, University of Florida COG Program
2001-2008 Member, COG Adolescent and Young Adult Committee
2001-present Member, COG AALL01B1 Study Committee: Multiparemeter flow cytometry for assessment of early marrow response in pediatric acute lymphoblastic leukemia: A companion study to CCG 1991
2002-2007 Vice-Chairman (Laboratory Biology), ALL Committee, COG
2003-present Member, COG 9407 Study Committee: Induction intensification and allogeneic transplant in infant ALL: A Children’s Oncology Group pilot study
2003-present Member, COG AALL03B1 Study Committee: Classification of Acute Lymphoblastic Leukemia
2003-present Member, COG AALL0232 Study Committee: Higher Risk B-precursor ALL
2003-present Member, COG AALL0331 Study Committee: Post-induction intensification for children with standard risk acute lymphoblastic leukemia
2004-present Member, COG ABTR04B1 Study Committee: Establishing continuous cell lines from pediatric cancers for biological and pre-clinical therapeutic studies
2004 Member, Search Committee for COG Group Statistician
2005-present Member, COG AALL0433 Study Committee Therapy for “Intermediate Risk” relapse of B-precursor acute lymphoblastic leukemia
2005-present Chair, COG AALL05B1 Study A COG Protocol for Collecting and Banking Pediatric Acute Lymphoblastic Leukemia Research Specimens
2005-present Member, COG AALL0434 Study Committee: Intensified Methotrexate, Nelarabine (Compund 506U78; IND # 52611) and Augmented BFM Therapy for Children and Young Adults with Newly Diagnosed T-cell Acute Lymphoblastic Leukemia
2006-present Member, COG ABTR02B1 Study Committee: Genetic polymorphisms in ALL samples submitted to gene array analysis
2006-present Chair, COG AALL06B1 Study Childhood Cancer Therapeutically Applicable Research to Generate Effective Treatments (TARGET) Initiative High-Risk ALL Pilot Project: Application of Array-Based Methods and Gene Re-sequencing to Identify Candidate Molecular Targets for High-Risk Pediatric Acute Lymphoblastic Leukemia
2007-present Member, COG AALL0631 Study Committee: A Study of Risk Directed Therapy for Infants with ALL: Randomization of Highest Risk Infants to Intensive Chemotherapy +/- FLT3 Inhibitiion (CEP-701, Lestaurtinib; IND #76431)
2007-present Member, COG AALL0622 Study Committee: Intensified tyrosine kinase inhbitor therapy in Philadelphia chromosome positive-acute lymphoblastic leukemia
2007-present Chairman, ALL Committee, COG
2007-present Member, COG AALL07P4 Study Committee: A Pilot Study of Intravenous EZN-2285 (SC-PEG E. coli L-asparaginase, IND# 100594) or Intravenous Oncaspar® in the Treatment of Patients with High-Risk Acute Lymphoblastic Leukemia
2008-present Member, COG AALL08P1 Study Committee: Intensified PEG-Asparaginase in High Risk Acute Lymphoblastic Leukemia: A Pilot Study
2008-present Member, COG AALL06N1 Study Committee: A study of neurocognitive function in children treated for acute lymphoblastic leukemia
2008-present Member, COG AALL07P1 Study Committee: A Phase Ib/II Trial of Bortezomib (PS-341, Velcade() in Combination with Intensive Re-Induction Therapy for Children with Relapsed Acute Lymphoblastic Leukemia (ALL)
2008-present Member, COG AALL02P2 Study Committee Treatment of Late Isolated Extramedullary Relapse from Acute Lymphoblastic Leukemia (ALL) (Initial CR1 > 18 months)
2008-present Member, COG AML Biology Committee
2009-present Vice-Chair, COG AALL08B2 Study Committee: Genome-Wide Interrogations in Childhood Acute Lymphoblastic Leukemia (ALL)
2009-present Member, COG AALL08B1 Study Committee: A Classification Trial to Risk Stratify Children with Newly Diagnosed B-Precursor Acute Lymphoblastic Leukemia (ALL)
2009-present Member, COG AALL09B1 Study Committee: Biological Correlates with T-cell Acute Lymphoblastic Leukemia (T-ALL) Gene Expression and Clinical Outcome
2009-present Member, COG AALL0932 Study Committee: Treatment of Patients with Newly Diagnosed Standard Risk B-Precursor Acute Lymphoblastic Leukemia (ALL)
2009-present Member, COG ADVL1011 Study Committee: A Phase I Study of JAK Inhibition INCB18424 in Children with Relapsed or Refractory Solid Tumors, Leukemias, and Myeloproliferative Disorders
2010-present Member, COG ACCL1033 Study Committee: A Comprehensive Approach to Improve Medication Adherence in Pediatric ALL
2010-present Member, COG AALL10B2 Study Committee: Identifying Rare Genetic Variants Involved in High Risk Acute Lymphoblastic Leukemia (ALL) Via Pooled DNA Sequencing
2010-present Member, COG AALL1131 Study Committee: Treatment of Newly Diagnosed High Risk B-precursor Acute Lymphoblastic Leukemia ALL
2011-present Member, COG ADVL1114 Study Committee: A Phase I Trial of Temsirolimus (CCI-779, Pfizer, Inc.) in Combination with Intensive Re-Induction Therapy for Children with Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkin Lymphoma
PEDIATRIC ONCOLOGY EXPERIMENTAL THERAPEUTICS INVESTIGATORS CONSORTIUM (POETIC)
2002-2007 Founding Member and University of Florida Principal Investigator
2004-2008 Member study committee, A multicenter phase I clinical trial of 17-N-allylamino-17-demethoxy geldanamycin (17-AAG, NSC# 330507) in patients with recurrent/refractory pediatric solid tumors (Ewing’s sarcoma, desmoplastic small round cell tumor, osteosarcoma, neuroblastoma, and rhabdomyosarcoma), and leukemia, NCI protocol number 6323
2005-2008 Member study committee, CA225085 Phase I study of Erbitux (Cetuximab) in Refractory Solid Tumors: Characterization of serum pharmacokinetics, safety and efficacy of cetuximab when combined with irinotecan
2005-2009 Member study committee, A multi-center phase Ib Study of Oxaliplatin (NSC#266046) in Combination with Fluorouracil and Leucovorin in pediatric patients with advanced solid tumors, NCI protocol number 6952
SUNSHINE PROJECT
2005-2008 Co-Chair, Clinical Trials Core
REGIONAL AND NATIONAL COMMITTEES
2001-2004 Member, Intergroup Specimens Banking Committee, National Cancer Institute
2001-2003 Member, Childhood Cancer Subcommittee, Florida Division of the American Cancer Society
04. Member, Program Committee (Pediatric Subcommittee), American Society of Clinical Oncology
2003-2004 Treasurer, The Climb for Cancer Foundation
05. Member, Florida Cancer Control and Research Advisory Committee
2003-2006 Vice-President, Florida Association of Pediatric Tumor Programs
2001-2007 Florida Association of Pediatric Tumor Programs, Executive Committee Member
2003-present Member, Board of Directors, The Climb for Cancer Foundation
2003-2007 Member, Board of Directors, STOP! Children’s Cancer, Inc.
2003-2007 Member, Childhood Cancer Advisory Council, Florida Division of the American Cancer Society (appointed by Governor)
2003-2007 Board of Directors, Greater Orlando Children’s Miracle Network
2007. Member, Scientific Committee on Pediatric Hematology, American Society of Hematology
2004-2010 Member, Group Banking Committee, National Cancer Institute
2004-present Member, Board of Directors, Keira Grace Foundation
2005 Faculty Member and Small Group Leader, American Society of Hematology Clinical Research Training Institute
2006 Faculty Member and Small Group Leader, American Society of Hematology Clinical Research Training Institute
2007 Executive Planning Committee, Stem Cell Transplantation in Children: Current Results and Controversies—Meeting #9
2007 Faculty Member and Small Group Leader, American Society of Hematology Clinical Research Training Institute
2008-2010 Member, Oversight Committee, American Society of Hematology Clinical Research Training Institute
2008 Organizer, American Society of Pediatric Hematology/Oncology Preconference Symposium Children’s Oncology Group acute lymphoblastic leukemia trial strategy: past, present and future; Cincinnati, OH; May 14th, 2008
2008-2010 Sickle Cell Anemia Advisory Committee, State of Colorado (appointed by Governor)
2008 Faculty Member and Small Group Leader, American Society of Hematology Clinical Research Training Institute
2009-2013 Member, Committee on Training Programs, American Society of Hematology
2009 Faculty Member, American Society of Hematology Clinical Research Training Institute
2009-2012 Member, American Society of Pediatric Hematology Oncology Review Course Committee
2010 Faculty Member and Small Group Leader, American Society of Hematology Clinical Research Training Institute
2010 American Society of Hematology Annual Meeting Daily News Author
2010-2012 American Society of Hematology Annual Meeting Planning Committee
2011 Chairperson; Pediatric Cancer – Basic Science Subcommittee of the Tumor Biology Section; 2011 AACR Program Committee
2011-present Member, National Cancer Institute Acute Lymphoblastic Leukemia Working Group
2011-present Track Leader (Pediatric Oncology), American Society of Clinical Oncology Scientific Program Committee
INSTITUTIONAL COMMITTEES
University of Colorado Health Sciences Center
1995 Molecular Pathology Search Committee, UCHSC
1996-2000 Clinical Practice Committee, Department of Pediatrics
1997 Manpower Utilization Committee, Division of Hematology-Oncology
1999 Hematology/Oncology Conference Schedule Committee (Chairman)
University of Florida Health Sciences Center
2003. UFSCC Protocol Review and Resource Utilization Committee (Member)
2001-2007 Interviewer, Intern Selection Committee, Department of Pediatrics
2001-2007 Medical Director’s Committee; University of Florida Shands Hospital
2001-2007 Member, University of Florida Shands Cancer Center (UFSCC)
2001-2007 Pediatric Oncology Multidisciplinary Working Group (Chair)
2001-2007 Hematologic Malignancy Multidisciplinary Working Group (Member)
2001-2007 Cancer Center Laboratory Planning Committee (Member)
2002-2007 Shands Children’s Hospital Executive Committee (Member)
2002-2007 Faculty Advisor for Pediatric Residents (Sutherland 02-05, Caicedo 04-05, LoDuca 04-07)
2004 Member, Search Committee for Assistant Director of UFSCC Clinical Trials Office
2004-2007 UFSCC Pilot Project Program Committee (Co-Chair)
2005-2007 Faculty Advisor for UF Undergraduate organization: College Students’ C.A.R.E.S.
2005-2007 Member, Data Safety Monitoring Committee for Transfusion of Autologous Umbilical Cord Blood to Reverse Hyperglycemia in Children with Type 1 Diabetes - A Pilot Study
2006-2007 Co-Chair, Pilot Project Review Committee for American Cancer Society Institutional Research Grants
2006-2007 Member, Department of Pediatrics/Shands Healthcare Logistics Committee
2007 Member, Children’s Miracle Network Leadership Board
University of Colorado Denver School of Medicine and The Children’s Hospital
2007-present Member, Executive Committee, University of Colorado Cancer Center
2007-2009 Member, Search Committee, Director of the University of Colorado Cancer Center
2008 Member, Clinical Operations Strategic Planning Group, The Children’s Hospital, Aurora CO
2008-present Member, Capital Committee, The Children’s Hospital, Aurora CO
2008-2009 Member, Cancer Center Workgroup Strategic Planning Committee, University of Colorado Hospital and the University of Colorado Cancer Center
2008-2010 Member, Cancer Center Outreach Committee, University of Colorado Cancer Center
2008-2010 Chair, Areas of Research Emphasis/Themes/Timing Committee; Department of Pediatrics Strategic Plan Team
2008-2010 Member, Executive Steering Committee; Department of Pediatrics Strategic Plan Team
2011- Member, Research Steering Committee, The Children’s Hospital
2011- Member, Search Committee, Chair of Department of Surgery; University of Colorado School of Medicine
2011- Interim Leader, Biology and Treatment of Childhood Cancer Research Emphasis Area
REVIEW AND REFEREE ACTIVITY
1994- Ad Hoc Reviewer, Blood, Leukemia, Genes, Chromosomes & Cancer, Molecular and Cellular Biology, Proc Natl Acad Sci USA, Journal of Pediatric Hematology/Oncology, Hematologica, Bone Marrow Transplantation, Journal of Clinical Oncology, Pediatric Blood and Cancer
1995-2000 Children’s Cancer Group grant and research proposal reviews
7/96 NIH, Biological Sciences Study Section, P01 Site Visit
1/97 NIH, Biological Sciences Study Section, P01 Site Visit
2/2000 NIH, Biological Sciences Study Section, P01 Site Visit
1999. Member, Scientific Advisory Board, Cancer League of Colorado
2000-present Children’s Oncology Group grant and research proposal reviews
2000 American Society of Hematology Abstract Review Committee
4/2002 NIH, Ad Hoc Member of Review Committee for PAR-01- 061 and 062
Phased Application Awards in Cancer Prognosis and Prediction
11/17-19/02 Department of Defense, Member Review Committee for Congressionally Directed Medical Research Programs, 2002 Chronic Myelogenous Leukemia Cancer Research Programs
2002 American Society of Hematology Abstract Review Committee
2003-2006 Editorial Board, Journal of Clinical Oncology
1/2004 The Hospital for Sick Children Career Development Awards; Toronto, Ontario, Canada; Ad Hoc Reviewer
3/2004 Michael Smith Foundation for Health Research Scholar Awards; Vancouver, British Columbia, Canada; Ad Hoc Reviewer
2004 American Society of Hematology Abstract Review Committee
2005 External referee, Ph.D. Thesis committee, University of Western Australia; Perth, Western Australia
2006 Société Française de lutte contre les Cancers et leucémies de l’Enfant et de l’adolescent Grant Review Committee
2006-2011 Alex’s Lemonade Stand Grant Review Committee
2007- Editorial Board, Leukemia
2009 Study Section Member, American Society of Hematology Alternative Training Pathway Grants
2010 European Hematology Association Annual Meeting Abstract Review Committee
2010 Study Section Member, American Society of Hematology Clinical Research Training Institute Applications
2009- Editorial Board, Leukemia Research
2009- Editorial Board, Pediatric Blood and Cancer
2010- Editorial Advisory Board, PDQ Pediatric Treatment
2010 American Society of Hematology Abstract Review Committee
2010 SIOP Annual Meeting Award Selection Committee
2011 Chairperson; Pediatric Cancer – Basic Science Subcommittee of the Tumor Biology Section of the 2011 AACR Program Committee
2011 American Society of Hematology Trainee Research Award Review Committee
2011 Hyundai Hope on Wheels Medical Review Committee
REGULATORY ACTIVITIES
2/2/2011 External expert; Pediatric Dasatinib Scientific Advice Working Party; European Medicines Agency; London, UK (without compensation)
2/8/2011 External expert; Clofarabine and Accelerated Approval commitments; Oncology Drugs Advisory Committee; Food and Drug Administration; Washington, D.C. (without compensation)
TEACHING
2002. GMS 6065 Fundamentals of Cancer Biology: 1 hour lecture “Leukemia”
2003. GMS 6065 Fundamentals of Cancer Biology: 1 hour lecture “Leukemia”
2004. GMS 6065 Fundamentals of Cancer Biology: 1 hour lecture “Leukemia”
2005. GMS 6065 Fundamentals of Cancer Biology: 1 hour lecture “Leukemia”
RESEARCH GRANTS AND CONTRACTS (DIRECT COSTS)
Currently Active Grant Awards
Children’s Oncology Group Chair’s Grant (2 U10 CA98543-Reaman) Subcontract #18684; 3/1/08-2/28/13; Subcontract for support of Dr. Hunger’s role as Chair of the COG ALL Committee; 20% effort and 20% salary support
Children’s Oncology Group Chair’s Grant (2 U10 CA98543-Reaman) Subcontract #20474; 3/1/10-2/28/11; Subcontract for Dr. Hunger’s role in AALL06N1 under the Best Pharmaceuticals for Children Award; 5% effort and 5% salary support
Leukemia and Lymphoma Society (LLS 7372-07 Felix); 10/1/06-9/30/11; Specialized Center of Research in Targeted Therapies for Infant Leukemia (SCOR); 2% effort and 2% salary support
NIH 2T32CA082086-11A1 (Hunger/Graham); 7/1/11-6/30/16; Postgraduate Training in Pediatric Oncology
NIH NCI 1 CA148529-02 (Loh/Hunger/Reaman); 10/1/09-9/30/11; Grand Opportunities Grant: Targeted Therapies for Childhood Acute Lymphoblastic Leukemia
NIH NCI 1RC1CA145707-01 (Mullighan/Willman); 10/1/09-9/30/11; Challenge Grant: Genomic Analysis of Adolescent and Young Adult Acute Lymphoblastic Leukemia; 2.5% effort and 0% salary support
Supplement to Children’s Oncology Group Chair’s Grant (2 U10 CA98543-Reaman): Childhood Cancer TARGET (Therapeutically Applicable Research to Generate Effective Treatments) Initiative Expansion – Tissue Collections and Characterization of High Risk Acute Lymphoblastic Leukemia (Hunger/Reaman); 10/1/09-9/30/11
PAR 10-106 Strategic Partnerships to Evaluate Cancer Signatures (SPECS II); Molecular Signatures For Outcome Prediction And Therapeutic Targeting In ALL (Willman/Hunger); 4/01/2011-03/31/2016; 15% effort and 15% salary support
Prior Grant Awards
NIH U24 CA114766 (Reaman); 6/1/05-5/31/10; COG Specimen Banks Advance Pediatric Cancer
Pediatric Cancer Foundation Sunshine Project; 7/1/08-6/30/09; Subcontract with H. Lee Moffitt Cancer Center and Research Institute for support of Dr. Hunger’s role as Co-Chair of Clinical Trials Core
Children’s Oncology Group Chair’s Grant (2 U10 CA98543-Reaman); 3/1/03-2/29/08; Subcontract for support of Dr. Hunger’s role as Vice Chair (Biology) of the COG ALL Committee
Children’s Oncology Group Chair’s Grant (U10 CA98543-Reaman); 3/1/03-9/30/07; Subcontract 11459 for support of Dr. Hunger’s role as Principal Investigator of the University of Florida COG Program
Children’s Oncology Group Chair’s Grant (U10 CA98543-Reaman); 3/1/07-2/28/08; Per case reimbursement Agreement 98543-1095 for Director of University of Florida COG Program
CA225085 Phase I study of Erbitux (Cetuximab) in Refractory Solid Tumors: Characterization of serum pharmacokinetics, safety and efficacy of cetuximab when combined with irinotecan; 8/1/05-7/31/07; Per case reimbursement (Bristol Myers Squibb/Imclone); Stephen P. Hunger, M.D., local site principal investigator.
U01 AI54736 (Marr); Galactomannan enzyme linked immunoassay as an early diagnostic test for invasive aspergillosis in pediatric patients undergoing intensive chemotherapy or hematopoietic stem cell transplant; 11/15/04-12/31/06; Per case reimbursement (NIH); Stephen P. Hunger, M.D., local site principal investigator
STOP! Children’s Cancer Foundation; Preclinical development of Flavopiridol regimens for treatment of relapsed childhood leukemia; 4/01/04-3/31/06
R21 CA 107437-02 (National Cancer Institute); Measuring Asparagine Synthetase expression in leukemia; 7/1/04-6/30/06; Stephen P. Hunger, M.D., Principal Investigator.
Children’s Oncology Group Chair’s Grant (U10 CA98543-02 Reaman); 3/1/04-2/28/05; Subcontract 12784 for support of Dr. Hunger’s role as Vice Chair (Biology) of the COG ALL Committee
Children’s Oncology Group Chair’s Grant (U10 CA98543-02 Reaman); 3/1/04-2/28/05; Subcontract 12784 for support of Dr. Hunger’s role as Principal Investigator of the University of Florida COG Program
Children’s Oncology Group Chair’s Grant (U10 CA98543-02 Reaman); 3/1/04-2/28/05; Per case reimbursement Agreement 98543-1095 for Director of University of Florida COG Program
National Heart, Lung & Blood Institute (N01-HB67132); COBLT (Unrelated donor umbilical cord blood as an alternative source of stem cells for transplantation); 6/20/03-6/30/04; Per case reimbursement as PI of COBLT for University of Florida; Stephen P. Hunger, M.D., Principal Investigator.
Children’s Oncology Group Chair’s Grant (U10 CA98543-01Reaman); 3/1/03-2/29/04; Subcontract 11165 for support of Dr. Hunger’s role as Vice Chair (Biology) of the COG ALL Committee
Children’s Oncology Group Chair’s Grant (U10 CA98543-01Reaman); 3/1/03-2/29/04; Subcontract 11459 for support of Dr. Hunger’s role as Principal Investigator of the University of Florida COG Program
Children’s Oncology Group Chair’s Grant (U10 CA98543-Reaman); 3/1/05-2/28/06; Per case reimbursement Agreement 98543-1095 for Director of University of Florida COG Program
Children’s Oncology Group Chair’s Grant (U10 CA30969-Reaman); 1/1/02-2/28/03; Subcontract for support of Dr. Hunger’s role as Vice Chair (Biology) of the COG ALL Committee; 10% effort and 10% salary support
American Cancer Society Research Project Grant (LBC 97-463); Functional analyses of the t(17;19)-ALL chimera E2A-HLF; 7/1/99-6/30/2003; 20% effort and 20% salary support; Stephen P. Hunger, M.D., Principal Investigator.
Leukemia Society of America Translational Research Award; Molecular Genetics of Relapsed Childhood ALL; 10/1/98-9/30/2001; 30% effort and 30% salary support; Stephen P. Hunger, Principal Investigator
The Loewenstern Family Foundation; Identification of Genes Involved in Progression of Childhood ALL via Comparative Genomic Hybridization; 10/1/98-9/30/2001; 5% effort and 0% salary support; Stephen P. Hunger, Principal Investigator
The Monfort Family Foundation; Identification of genes involved in variant (1;19) translocations in childhood ALL; 5% effort and 5% salary support; Stephen P. Hunger, Principal Investigator
Children’s Cancer Group Chairman’s Award from NCI (2 U10 CA13539-27); 3% salary support for efforts as Chairman Young Investigators Committee; Archie Bleyer, Principal Investigator
Cancer League of Colorado; Identification and characterization of a novel t(1;19) translocation in acute lymphoblastic leukemia; Lia Gore Quinones, Principal Investigator (Post-doctoral fellowship for Dr. Gore)
Leukemia Research Foundation; Identification and characterization of a novel t(1;19) translocation in acute lymphoblastic leukemia; 7/99-6/00; Lia Gore Quinones, Principal Investigator (Post-doctoral fellowship for Dr. Gore)
NIH Shannon Award (1 R55 CA74091-01A1); Functional Analyses of the t(17;19)-ALL Chimera E2A-HLF; 4/1/98-3/31/2000; Stephen P. Hunger, M.D., Principal Investigator. Relinquished 9/1/99 and replaced by ACS RPG.
Howard Hughes Medical Institute/University of Colorado School of Medicine/Individual Investigator Award; Interrogating the Anti-Apoptotic Properties of E2A-HLF; 5% effort and 0% salary support; Stephen P. Hunger, Principal Investigator
The Children’s Hospital Research Institute Professional Development Award; Identification of E2A-HLF Target Genes; Stephen P. Hunger, M.D., Principal Investigator
National Childhood Cancer Foundation Translational Research Pilot Grant; The Role of p16INK4A/p15 INK4B Deletions in Relapsed ALL; 1/98-12/98; 5% effort and 0% salary support; Stephen P. Hunger, Principal Investigator
UCHSC Cancer Center Wines for Life Fellowship Grant; Retrospective analysis of prognostic import of TEL gene rearrangements and hyperdiploidy on treatment outcome for children with standard risk ALL treated with a single delayed intensification; 5% effort and 0% salary support; Kelly W. Maloney, Principal Investigator (Post-doctoral fellowship for Dr. Maloney)
Children’s Cancer Research Foundation; Retrospective analysis of prognostic import of TEL gene rearrangements and hyperdiploidy on treatment outcome for children with standard risk ALL treated with a single delayed intensification; 5% effort and 5% salary support; Kelly W. Maloney, Principal Investigator
Leukemia Research Foundation; Identification of E2A-HLF target Genes; 7/97-6/98; 40% effort and 0% salary support; Stephen P. Hunger, Principal Investigator
Laura and Greg Norman Research Fellowship Award from the National Childhood Cancer Foundation; 7/96-6/98; 5% effort and 0% salary support; Kelly W. Maloney, Principal Investigator (Post-doctoral fellowship for Dr. Maloney)
Ladies Auxiliary to the Veterans of Foreign Wars Award; Detection of Minimal Residual Disease in t(1;19)+ ALL 10/95-9/96; Stephen P. Hunger, M.D., Principal Investigator
American Cancer Society Institutional Research Grant; Analysis of Transforming Properties of the Chimeric Transcription Factor E2A-HLF; 9/95-8/96; Stephen P. Hunger, M.D., Principal Investigator
American Society of Hematology Scholar Award; Identification of Genetic Changes Involved in the Progression of Childhood ALL; 7/95-6/97; 50% effort and 50% salary support; Stephen P. Hunger, M.D., Principal Investigator
Cancer League of Colorado; Identification of Genetic Changes Involved in the Progression of Childhood ALL; Stephen P. Hunger, M.D., Principal Investigator
Maxfield Foundation; Detection of Minimal Residual Disease in t(1;19)+ ALL; 3/95-9/95; Stephen P. Hunger, M.D., Principal Investigator
PUBLICATIONS
Original Articles
1. Mellentin JD, Nourse J, Hunger SP, Smith SD, and Cleary ML: Molecular analysis of the t(1;19) breakpoint cluster region in pre-B cell ALL. Genes, Chromosomes and Cancer 2: 239-247, 1990. PMID: 2078515
2. Suryanarayan K, Hunger SP, Kohler S, Carroll AJ, Crist WM, Link MP, and Cleary ML: Consistent involvement of the BCR gene by 9;22 breakpoints in pediatric acute leukemias. Blood 77: 324-330, 1991. PMID: 1985699
3. Hunger SP, Galili N, Carroll AJ, Crist WM, Link M, and Cleary ML: The t(1;19)(q23;p13) results in consistent fusion of E2A and PBX1 coding sequences in acute lymphoblastic leukemias. Blood 77: 687-693, 1991. PMID: 1671560
4. Hunger SP, Sklar J, and Link MP: Acute lymphoblastic leukemia occurring as a second malignant neoplasm in childhood: Report of three cases and review of the literature. Journal of Clinical Oncology 10: 156-163, 1992. PMID: 1309379
5. Hunger SP, Ohyashiki K, Toyama K, and Cleary ML: HLF, a novel hepatic bZIP protein, shows altered DNA-binding properties following fusion to E2A in t(17;19) acute lymphoblastic leukemia. Genes and Development 6: 1608-1620, 1992. PMID: 1516826
6. Hunger SP, Tkachuk DC, Amylon MD, Link MP, Carroll AJ, Welborn JL, Willman CL, and Cleary ML: Consistent HRX involvement in de novo and secondary leukemias with diverse chromosome 11q23 abnormalities. Blood 81: 3197-3203, 1993. PMID: 8389614
7. Borowitz MJ, Hunger SP, Carroll AJ,. Shuster JJ, Pullen DJ, Steuber PJ, and Cleary ML: Predictability of the t(1;19)(q23;p13) from surface antigen phenotype. Implications for screening cases of childhood ALL for molecular analysis. A Pediatric Oncology Group study. Blood 82: 1086-1091, 1993. PMID: 8353275
8. Hunger SP, Devaraj PE, Foroni L, Secker-Walker LM, and Cleary ML: Two types of genomic rearrangements create alternative E2A-HLF fusion proteins in t(17;19)-ALL. Blood 83: 2970-2977, 1994. PMID: 8180393
9. Hunger SP, Brown R, and Cleary ML: DNA-binding and transcriptional regulatory properties of hepatic leukemia factor (HLF) and the t(17;19) acute lymphoblastic leukemia chimera E2A-HLF. Molecular and Cellular Biology 14: 5986-5996, 1994. PMID: 8065331
10. Hunger SP, Link MP, and Donaldson SS: ABVD/MOPP and low dose involved field radiotherapy in Pediatric Hodgkin's disease: The Stanford experience. Journal of Clinical Oncology 12: 2160-2166, 1994. PMID: 7523608
11. Hunger SP: Chromosomal translocations involving the E2A gene in acute lymphoblastic leukemia: Clinical features and molecular pathogenesis. Blood 87:1211-1224, 1996. PMID: 8608207
12. Hunger SP, Li S, Fall MZ, Naumovski L, Cleary ML: The proto-oncogene HLF and the related bZIP protein TEF display highly similar DNA-binding and transcriptional regulatory properties. Blood 87:4607-4617, 1996. PMID: 8639829
13. Sifontes MT, Nuss R, Hunger SP, Wilimas J, Jacobson LJ, Manco-Johnson MJ: The factor V Leiden mutation in children with cancer and thrombosis. British Journal of Haematology 96: 484-489, 1997. PMID: 9054652
14. Maloney KW, Rubnitz JE, Cleary ML, Frankel LS, Hakami N, Link MP, Pullen DJ, Hunger SP: Lack of ETV6 (TEL) gene rearrangements or p16INK4A/p15INK4B homozygous gene deletions in infant acute lymphoblastic leukemia. Leukemia 11: 979-983, 1997. PMID: 9204978
15. Hunger SP, Sun T, Boswell AF, Carroll AJ, McGavran L: Hyperdiploidy and E2A-PBX1 fusion in an adult with t(1;19)+ acute lymphoblastic leukemia: Case report and review of the literature. Genes, Chromosomes and Cancer 20: 392-398, 1997. PMID: 9408756
16. Sifontes MT, Nuss R, Hunger SP, Jacobson LJ, Waters JL, Manco-Johnson MJ: Correlation between the functional assay for activated protein C resistance and Factor V Leiden in the neonate. Ped Res 42: 776-778, 1997. PMID: 9396556
17. Sifontes MT, Nuss R, Hunger SP, Waters JL, Jacobson LJ, Manco-Johnson MJ: Activated protein C resistance and the factor V Leiden mutation in children with thrombosis. Amer. J Hematol 57: 29-32, 1998. PMID: 9423813
18. Hunger SP, Fall MZ, Camitta BM, Carroll AJ, Link MP, Lauer SJ, Mahoney DH, Pullen DJ, Shuster JJ, Steuber CP, Cleary ML: E2A-PBX1 chimeric transcript status at end of consolidation does not predict treatment outcome in childhood acute lymphoblastic leukemias with a t(1;19)(q23;p13): A Pediatric Oncology Group study. Blood 91: 1021-1028, 1998. PMID: 9446665
19. Hunger SP, Cleary ML. What significance should we attribute to the detection of MLL fusion transcripts? Blood 92: 709-711, 1998. PMID: 9680337
20. Silliman CC, McGavran L, Wei Q, Miller LA, Li S, Hunger SP. Alternative splicing in wild-type AF10 and CALM cDNAs and in AF10-CALM and CALM-AF10 fusion cDNAs produced by the t(10;11)(p13-14;q14-21) suggests a potential role for truncated AF10 polypeptides. Leukemia 12:1404-1410, 1998. PMID: 9737689
21. Maloney, KW, McGavran L, Odom LF, Hunger SP. Different patterns of homozygous p16INK4A and p15INK4B deletions in childhood acute lymphoblastic leukemias containing distinct E2A translocations. Leukemia 12: 1417-1421, 1998. PMID: 9737691
22. Hunger SP, McGavran L, Meltesen L, Parker NB, Kassenbrock K, Bitter M: Oncogenesis in utero: Fetal demise due to acute myelogenous leukemia with an MLL translocation. Br. J. Haematol 103: 539-542, 1998. PMID: 9827932
23. Leon RP, Hedlund T, Meech s, Li S, Schaack J, Hunger SP, Duke RC, DeGregori J. Adenoviral-mediated gene transfer in lymphocytes. Proc. Natl Acad Sci USA 95: 13159-13164, 1998. PMID: 9789058
24. Maloney KW, McGavran L, Odom LF, Hunger SP. Acquisition of p16INK4A and p15INK4B gene abnormalities between initial diagnosis and relapse in children with acute lymphoblastic leukemia. Blood 93: 2380-2385, 1999. PMID: 10090949
25. Iiboshi Y, Papst PJ, Hunger SP, Terada N. L-Asparaginase inhibits the rapamycin-targeted signaling pathway. Biochemical & Biophysical Research Communications 260: 534-539, 1999. PMID: 10403802
26. Maloney KW, McGavran L, Murphy JM, Odom LF, Stork L, Wei Q, Hunger SP. TEL-AML1 fusion identifies a subset of children with standard risk acute lymphoblastic leukemia who have an excellent prognosis when treated with therapy that includes a single delayed intensification. Leukemia 13: 1708-1712, 1999. PMID: 10557042
27. Kadan-Lottick NS, Stork L, Ruyle SZ, Koyle M, Hunger SP, McGavran L. Cytogenetic abnormalities in a case of botryoid rhabdomyosarcoma. Medical and Pediatric Oncology 34: 293-295, 2000. PMID: 10742076
28. Gore L, Ess J, Bitter M, McGavran L, Meltesen L, Wei Q, Hunger SP. Protean clinical manifestations in children with leukemias containing MLL-AF10 fusion. Leukemia 14: 2070-2075, 2000. PMID: 11187895
29. Boomer T, Varella-Garcia M, McGavran L, Metelsen L, Olsen AS, Hunger SP. Detection of E2A translocations via fluorescence in situ hybridization. Leukemia 15: 95-102, 2001. PMID: 11243406
30. Li S, Hunger SP. The DBP transcriptional activation domain is highly homologous to that of HLF and TEF and is not responsible for the tissue type-specific transcriptional activity of DBP. Gene 263: 239-245, 2001. PMID: 11223263
31. Meech SJ, McGavran L, Odom LF, Liang X, Meltesen L, Gump J, Wei Q, Carlsen S, Hunger SP. An unusual childhood extramedullary hematologic malignancy with natural killer cell properties that contains tropomyosin 4-anaplastic lymphoma kinase gene fusion. Blood 98: 1209-1216, 2001. PMID: 11493472
32. Gump J, McGavran L, Wei Q, Hunger SP. Analysis of TP53 mutations in relapsed childhood acute lymphoblastic leukemia. Journal of Pediatric Hematology/Oncology 23: 416-419, 2001. PMID: 11878574
33. Drabkin HA, Parsy C, Ferguson K, Guilhot F, Lacotte L, Roy L, Zeng C, Baron A, Hunger SP, Varella-Garcia M, Gemmill R, Brizard F, Brizard A, Roche J. Quantitative Hox expression In chromosomally defined subsets of acute myelogenous leukemia. Leukemia 16:186-195, 2002. PMID: 11840284
34. Moos PJ, Raetz EA, Carlson MA, Szabo A, Smith FE, Willman C, Wei Q, Hunger SP, Carroll WL. Identification of gene expression profiles that segregate patients with childhood leukemia. Clinical Cancer Research 8: 3118-30, 2002. PMID: 12374679
35. Wiemels JL, Leonard BC, Wang Y, Segal MR, Hunger SP, Smith MT, Crouse V, Ma X, Buffler PA, Pine SR. Site-specific translocation and evidence of postnatal origin of the t(1;19) E2A-PBX1 fusion in childhood acute lymphoblastic leukemia. Proc. Natl Acad Sci USA 99: 15101-15106, 2002. PMID: 12415113
36. Foa R, Vitale A, Mancini M, Cuneo A, Mecucci C, EliA C, Lombardo R, Saglio G, Torelli G, Annino L, Specchia G, Damasio E, RecchiA A, Di Raimondo F, Tafuri A, FazI P, Hunger SP, MandellI F. The E2A-PBX1 fusion characterizes a subset of adult acute lymphoblastic leukemia with distinct biologic and clinical features. British Journal of Haematology 120: 484-487, 2003. PMID: 12580965
37. Toretsky JA, Jenson J, Sun C-C, Eskenazi AE, Campbell A, Hunger SP, Caires A, Frantz C, Hill JL, Stamberg J. Translocation (11;15;19): a highly specific chromosome rearrangement associated with poorly differentiated thymic carcinoma in young patients. American Journal of Clinical Oncology 26: 300-306, 2003. PMID: 12796605
38. Casillas JN, Woods WG, Hunger SP, McGavran L, Alonzo TA, Feig SA. Prognostic implications of t(10;11) translocations in childhood acute myelogenous leukemia (AML): A Report from the Children’s Cancer Group. Journal of Pediatric Hematology/Oncology 25: 594-600, 2003. PMID: 12902910
39. Dharnidharka V, Douglas VK, Hunger SP, Fennell RS. Hodgkin’s disease after post transplant lymphoproliferative disease in a renal transplant recipient. Pediatric Transplantation 8: 87-90, 2004. PMID: 15009846
40. Liang X, Odom LF, Meech SJ, Bitter MA, Ryder JW, Hunger SP, Lovell MA, Wei Q, Meltesen R, McGavran. Assessment of t(2;5)(p23;q35) translocation and variants in ALK positive anaplastic large cell lymphoma. American Journal of Clinical Pathology 121: 496-506, 2004. PMID: 15080301
41. van der Burg M, Poulsen TS, Hunger SP, Beverloo HB, Smit EME, Vang-Nielsen K, Langerak AW, van Dongen JM. Split-signal FISH for detection of chromosome aberrations n acute lymphoblastic leukemia. Leukemia 18: 895-908, 2004. PMID: 15042105
42. Sutherland N, Gonzalez-Peralta R, Douglas-Nikitin V, Hunger SP. Polycythermia vera in a child following treatment for acute lymphoblastic leukemia. Journal of Pediatric Hematology/Oncology 26: 315-319, 2004. PMID: 15111786
43. Trobaugh-Lotrario AD, Kletzel M, Quinones RR, McGavran L, Hunger SP, Malcolm J, Schissel D, Hild E, Giller RH. Monosomy 7 associated with pediatric acute myeloid leukemia and myelodysplastic syndrome: successful management by allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 35: 143-149, 2005. PMID: 15558042
44. Prima V, Gore L, Caires A, Boomer T, Yoshinari M, Imaizumi M, Varella-Garcia M, Hunger SP. Cloning and functional characterization of MEF2D/DAZAP1 and DAZAP1/MEF2D fusion proteins created by a variant t(1;19)(q23;p13.3) in acute lymphoblastic leukemia. Leukemia 19: 806-813, 2005. PMID: 15744350
45. Hollander MC, Patterson AD, Salvador JM, Anver MR, Perotti D, Hunger SP, Fornace AJ Jr. Gadd45a acts as a modifier locus for lymphoblastic lymphoma. Leukemia 19: 847-850, 2005. PMID: 15744335
46. Aricó M, Baruchel A, Bertrand Y, Biondi A, Conter V, Eden OB, Gadner H, Gaynon P, Horibe K, Hunger SP, Janka-Schaub G, Masera G, Nachman J, Pieters R, Schrappe M, Schmiegelow K, Grazia Valsecchi M, Pui CH. The seventh international childhood acute lymphoblastic leukemia workshop report: Palermo, Italy, January 29 to 30, 2005. Leukemia 19: 1145-1152, 2005. PMID: 15902295
47. Hunger SP, Winick NJ, Sather HN, Carroll WL. Therapy of low risk subsets of childhood acute lymphoblastic leukemia: when do we say enough? Pediatr Blood Cancer 45: 876-880, 2005. PMID: 16007585
48. Baudis M, Prima V, Tung YH, Hunger SP. ABCB1 over-expression and drug-efflux in acute lymphoblastic leukemia cell lines with t(17;19) and E2A-HLF expression. Pediatr Blood Cancer, 47: 757-764, 2006. Epub 2005 Oct 3. PMID: 16206189
49. Bhojwani D, Kang H, Moskowitz N, Min D-J, Lee K, Potter J, Davidson G, Borowitz M, Belitskaya-Levy I, Hunger SP, Willman C, Raetz E, Carroll WL. Biological pathways associated with relapse in childhood acute lymphoblastic leukemia. Blood 108: 711-717, 2006. PMID: 16822902
50. Hunger SP. NOTCH1 mutations, outcome in T-ALL, and designing targeted therapy. Blood 108: 1117-1118, 2006.
51. Chen I-M, Chakerian A, Devidas M, Borowitz MJ, Hunger SP, Willman CL, Viswanatha DS. Resolution of ambiguous low-level positive quantitative polymerase chain reaction results in TEL-AML1 positive ALL using a post-PCR fluorescent oligoligation method. Br. J. Haematol 135: 358-361, 2006. Epub 2006 Sept 19. PMID: 16984387
52. Schultz KR, Pullen JK, Sather HN, Shuster JJ, Devidas M, Borowitz MJ, Carroll AJ, Heerema NA, Rubnitz JE, Loh ML, Raetz ER, Winick NJ, Hunger SP, Carroll WL, Gaynon PS, Camitta BM. Risk and response-based classification of childhood B-precursor acute lymphoblastic leukemia: A combined analysis of prognostic markers from the pediatric oncology group (POG) and Children’s Cancer Group (CCG). Blood 109(3):926-35, 2007. Epub 2006 Sep 26. PMID: 17003380
53. Bagatell R, Gore L, Egorin MJ, Ho R, Heller G, Boucher N, Zuhowski EG, Whitlock JA, Hunger SP, Narendran A, Katzenstein HM, Arceci RJ, Boklan JL, Herzog CE, Whitesell LJ, Ivy SP, Trippett TM. Phase I pharmacokinetic and pharmacodynamic study of 17-N-allylamino-17-demethoxygeldanamycin (17-AAG) in pediatric patients with recurrent or refractory solid tumors: A Pediatric Oncology Experimental Therapeutics Investigators Consortium study. Clinical Cancer Research 13: 1783-1788, 2007. PMID: 17363533
54. Keole S, Hunger SP. Management of Anaplastic Histology Wilms’ Tumor: The Impact of NWTS-5. Am J Heme Onc 6: 79-81, 2007.
55. Prima V, Hunger SP. Cooperative transformation by MEF2D/DAZAP1 and DAZAP1/MEF2D fusion proteins generated by the variant t(1;19) in acute lymphoblastic leukemia. Leukemia 21: 2470-2475, 2007. Epub 2007 Sept 27. PMID: 17898785
56. Su N, Pan Y-X, Zhou M, Harvey RC, Hunger SP, Kilberg MS. Correlation between asparaginase sensitivity and asparagine synthetase protein content, but not mRNA, in acute lymphoblastic leukemia cell lines. Pediatr Blood Cancer 50: 274-279, 2008. Epub 2007 May 18. PMID: 17514734
57. Yang F, Li Y, Braylan R, Hunger SP, Yang L-J. Pediatric T-Cell Post-Transplant Lymphoproliferative Disorder after Solid Organ Transplantation. Pediatr Blood Cancer 50: 415-418, 2008. Epub 2006 Oct 18. PMID: 17051534
58. Jackman KM, Hunger SP. Flavopiridol displays preclinical activity in acute lymphoblastic leukemia. Pediatr Blood Cancer 50: 772-778, 2008. Epub 2007 Nov 13. PMID: 18000861
59. Bhojwani D, Kang H, Menezes RX, Yang W, Sather H, Moskowitz NP, Min D-J, Potter JW, Harvey R, Hunger SP, Seibel N, Raetz EA, Pieters R, Relling MV, den Boer ML, Willman CL, Carroll, WL. Gene expression signatures predictive of early response and outcome in high-risk childhood acute lymphoblastic leukemia: A Children’s Oncology Group study. Journal of Clinical Oncology 26: 4376-4384, 2008. PMID: 18802149
60. Rubnitz J, Wichlan D, Devidas M, Shuster J, Linda SB, Kurtzberg J, Bell B, Hunger SP, Chauvent A, Pui C-H, Camitta B, Pullen J. Prospective Analysis of TEL Gene Rearrangements in Childhood Acute Lymphoblastic Leukemia: A Children’s Oncology Group Study. Journal of Clinical Oncology 26: 2186-2191, 2008. PMID: 18445843
61. Khan NI, Cisterne A, Devidas M, Shuster J, Hunger SP, Shaw P, Bradstock KF, Bendall LJ. Expression of CD44, but not CD44v6, predicts relapse in children with B cell progenitor ALL lacking adverse or favorable genetics. Leukemia and Lymphoma 49: 710-718, 2008. PMID: 18398738
62. Zhong C-h, Prima V, Liang X, Frye C, McGavran L, Meltesen L, Wei Q, Boomer T, Varella-Garcia M, Gump J, Hunger SP. E2A-NMP4 and P120-E2A fusion created by a cryptic t(12;19) in acute leukemia. Leukemia 22: 723-729, 2008. Epub 2008 Jan 10. PMID: 18185522
63. Borowitz MJ, Devidas M, Hunger SP, Bowman WP, Carroll AJ, Carroll WL, Linda S, Martin PL, Pullen DJ, Viswanatha D, Willman CL, Winick N, Camitta BM. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors. A Children’s Oncology Group study. Blood, 111: 5477-5485, 2008. Epub 2008 April 3. PMID: 18388178
64. Henry DD, Hunger SP, Braylan RC, Dharnidharka VR. Low viral load post-transplant lymphoproliferative disease (PTLD) localized within the tongue. Transpl Infect Dis. 10: 426-430, 2008. Epub 2008 Jul 22. PMID: 18657087
65. Raetz EA, Borowitz MJ, Devidas M, Linda SB, Hunger SP, Winick NJ, Camitta BM, Gaynon PS, Carroll WL. A re-induction platform for children with first marrow relapse: Results from Children’s Oncology Group (COG) study AALL01P2. Journal of Clinical Oncology 26: 3971-3978, 2008. PMID: 18711187
66. Abbatiello SE, Pan Y-Z, Zhou M, Wayne AS, Veenstra TD, Hunger SP, Kilberg MS, Eyler JR, Richards NGJ, Conrads TP. Mass spectrometric quantification of asparagine synthetase in circulating leukemia cells from acute lymphoblastic leukemia patients. Journal of Proteomics 71: 61-70, 2008. Epub 2007 Dec 5. PMID: 18541474
67. Nguyen K, Devidas M, Cheng SC, La M, Raetz EA, Carroll WL, Winick NJ, Hunger SP, Gaynon PS, Loh ML. Factors influencing survival after relapse from acute lymphoblastic leukemia: A Children’s Oncology Group study. Leukemia 22: 2142-2150, 2008. Epub 2008 Sep 25. PMID: 18818707
68. Yang YJ, Bhojwani D, Yang W, Cai X, Stocco G, Crews K, Wang J, Morrison D, Devidas M, Hunger SP, Willman CL, Raetz EA, Pui C-h, Evans WE, Relling MV, Carroll WL. Genome-wide copy number profiling reveals molecular evolution from diagnosis to relapse in childhood acute lymphoblastic leukemia. Blood 112: 4178-4183, 2008. Epub 2008 Sep 2. PMID: 18768390
69. Araya CE, Mehta MB, Gonzalez-Peralta RP, Hunger SP, Dharnidharka VR. Native kidney post-transplant lymphoproliferative disorder (PTLD) in a non-renal transplant patient. Pediatric Transplantation, 13: 495-498, 2009. Epub 2008 Jul 30. PMID: 18673359
70. Yang JJ, Cheng C, Yang W, Pei D, Cao X, Fan Y, Pounds SB, Neale G, Treviño LR, French D, Campana D, Downing JR, Evans WE, Pui C-H, Devidas M, Bowman WP, Camitta BM, Willman CL, Davies SM, Borowitz MJ, Carroll WL, Hunger SP, Relling MV. Genome-wide interrogations of germline genetic variation associated with treatment response in childhood acute lymphoblastic leukemia. Journal of the American Medical Association, 301: 393-403, 2009. PMID: 19176441
71. Garner R, Li Y, Gray BA, Zori R, Braylan R, Wall J, Hunger SP. Long-term disease control of refractory anaplastic large cell lymphoma with vinblastine. Journal of Pediatric Hematology/Oncology, 31:145-147, 2009. PMID: 19194204
72. Hunger SP, Sung L, Howard SC. Treatment strategies and regimens of graduated intensity for childhood acute lymphoblastic leukemia in low-income countries: A proposal. Pediatric Blood and Cancer, 52: 559-565, 2009. Epub 2009 Jan 6. PMID: 19127567
73. Mullighan CG, Su X, Zhang J, Radtke I, Phillips LAA, Miller CB, Ma J, Liu W, Cheng C, Schulman B, Harvey R, Chen I-M, Clifford R, Carroll WL, Reaman G, Bowman WP, Devidas M, Gerhard DS, Yang W, Relling MV, Shurtleff SA, Campana D, Borowitz MJ, Pui C-H, Smith M, Hunger SP, Willman C, Downing JR. Deletion of IZKF1 (Ikaros) is associated with poor prognosis in acute lymphoblastic leukemia. New England Journal of Medicine, 360: 470-480, 2009. Epub 2009 Jan 7. PMID: 19129520
74. Hunger SP, Loh KM, Baker KS, Schultz KR. Controversies of and unique Issues in hematopoietic cell transplantation for infant leukemia. Biol Blood Marrow Transplant 15(1 Suppl): 79-83, 2009. PMID: 19147083
75. Saxonhouse MA, Tarquino D, Carney PR, Bennett J, Smith A, Hunger SP, Geyer J. Low molecular weight heparin use in a case of non-cardiogenic multifocal perinatal thromboembolic stroke. Advances in Hematology, Epub 2009 Feb 16. PMID: 19946420
76. Nachman J, La M, Hunger SP, Heerema N, Gaynon PS, Hastings C, Mattano LA, Sather H, Devidas M, Fryer D, Steinherz P, Seibel NL. Young adults with acute lymphoblastic leukemia have an excellent outcome with chemotherapy alone and benefit from intensive post induction treatment: A report from the Children’s Oncology Group. Journal of Clinical Oncology, 27: 5189-5194, 2009. Epub 2009 Oct 5. PMID: 19805689
77. Schultz KR, Bowman WP, Aledo A, Slayton WB, Sather H, Devidas M, Villaluna D, Wang C, Pasut B, Davies SM, Eslinger T, Gaynon PS, Trigg M, Rutledge R, Burden L, Jorstad D, Carroll A, Heerema N, Winick N, Borowitz MJ, Hunger SP, Carroll WL, Camitta C. Improved early event free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukaemia: A Children's Oncology Group study. Journal of Clinical Oncology, 27: 5175-5181, 2009. Epub 2009 Oct 5. PMID: 19805687
78. Mullighan* CG, Zhang* J, Harvey* RC, Collins-Underwood JR, Schulman BA, Phillips LA, Tasian SK, Loh ML, Su X, Liu W, Devidas M, Atlas SR, Chen I-M, Clifford RJ, Gerhard DS, Carroll WL, Reaman GH, Smith M, Downing# JR, Hunger# SP, Willman# CL. JAK mutations in high-risk childhood acute lymphoblastic leukemia. Proc. Natl Acad Sci USA, 106: 9414-9418, 2009. Epub 2009 May 20. *CGM, JZ and RCH contributed equally; #JRD, SPH and CLW contributed equally. PMID: 19470474
79. Trippett TM, Herzog C, Whitlock JA, Wolff J, Kuttesch J, Bagatell R, Hunger S, Boklan J, Smith AA, Arceci RJ, Katzenstein HM, Harbison C, Zhou X, Lu H, Langer C, Weber M, Gore L. Phase I and pharmacokinetic study of cetuximab and irinotecan in children with refractory solid tumors: A study of the Pediatric Oncology Experimental Therapeutic Investigators’ Consortium. Journal of Clinical Oncology, 27: 5102-5209, 2009. Epub 2009 Sept 21. PMID: 19770383
80. Gutierrez A, Sanda T, Grebliunaite R, Cariacedo A, Salmena L, Ahn Y, Dahlberg S, Neuberg D, Moreau L, Winter SS, Zhang J, Protopopov A, Chin L, Pandolfi PP, Silverman L, Hunger SP, Sallan S, Look AT. PTEN and the PI3K/AKT Pathway in T-Cell Acute Lymphoblastic Leukemia. Blood 114: 647-650, 2009. Epub 2009 May 20. PMID: 19458356
81. Advani AS, Hunger SP, Burnett AK. Acute leukaemia in adolescents and young adults. Semin Oncol 36: 213-26, 2009. PMID: 19460579
82. Treviño LR, Yang W, French D, Hunger SP, Carroll WL, Devidas M, Willman C, Neale G, Downing J, Raimondi SC, Pui C-H, Evans WE, Relling MV. Germline genomic variants associated with childhood acute lymphoblastic leukemia. Nature Genetics, 41: 1001-1005, 2009. Epub 2009 Aug 16. PMID: 19684603
83. Biondi A, Baruchel A, Hunger S, Masera G, Schmiegelow K, Schrappe M, Pui CH. The eleventh international childhood acute lymphoblasic leukemia workshop report: Ponte di Legno, Italy, 6-7 May 2009. Leukemia, 23:2318-2324, 2009. Epub 2009 Nov 5. PMID: 19890375
84. Mullighan CG, Collins-Underwood JR, Phillips LAA, Loudin ML, Liu W, Zhang J, Ma J, Coustan-Smith E, Harvey RC, Willman CL, Mikhail FM, Meyer J, Carroll AJ, Williams RT, Cheng J, Heerema NA, Basso G, Pession A, Pui CH, Raimondi SC, Hunger SP, Downing JR, Carroll WL, Rabin KR. Rearrangement of CRLF2 in B-progenitor and Down syndrome associated acute lymphoblastic leukemia. Nature Genetics 41: 1243-1246, 2009. Epub 2009 Oct 18. PMID: 19838194
85. Kang H, Chen I-M, Wilson CS, Bedrick EJ, Harvey RC, Atlas SR, Devidas M, Mullighan CG, Wang X, Murphy M, Ar K, Wharton W, Borowitz MJ, Bowman WP, Bhojwani D, Carroll WL, Camitta B, Reaman GH, Smith MA, Downing JR, Hunger SP, Willman CL. Gene expression classifiers for relapse free survival and minimal residual disease improve risk classification and outcome prediction in pediatric B-precursor acute lymphoblastic leukemia. Blood 115: 1394-1405, 2010. Epub 2009 Oct 30. PMID: 19880498
86. Gaynon PS, Angiolillo AL, Carroll WL, Nachman JB, Trigg ME, Sather HN, Hunger SP, Devidas M. Long term results of the Children’s Cancer Group studies for childhood acute lymphoblastic leukemia 1983-2002: a Children’s Oncology Group report. Leukemia, 24: 285-297, 2010. Epub 2009 Dec 17. PMID: 20016531
87. Salzer WL, Devidas M, Carroll WL, Winick N, Pullen J, Hunger SP, Camitta BM. Long-term results of the Pediatric Oncology Group studies for childhood acute lymphoblastic leukemia 1984-2001: A report from the Children’s Oncology Group. Leukemia, 24: 355-370, 2010. Epub 2009 Dec 17. PMID: 20016527
88. Bercovitz RS, Greffe BS, Hunger SP. Acute tumor lysis syndrome in a 7-month-old with hepatoblastoma. Current Opinions Pediatrics 22: 113-116, 2010. Epub 2009 Nov 18. PMID: 19926992
89. Horton TM, Sposto R, Brown P, Reynolds CP, Hunger SP, Winick N, Raetz E, Carroll W, Arceci R, Borowitz M, Gaynon P, Gore L, Jeha S, Maurer B, Siegel SE, Biondi A, Kearns P, Narendran A, Silverman L, Smith M, Zwaan M, Whitlock J. Toxicity assessment of molecularly targeted drugs incorporated into multiagent chemotherapy regimens for pediatric acute lymphocytic leukemia (ALL): Review from an international consensus conference. Pediatric Blood and Cancer 54: 872-878, 2010. Epub 2010 Feb 1. PMID: 20127846
90. Gutierrez A, Sanda T, Ma W, Zhang J, Grebliunaite R, Dahlberg S, Neuberg D, Protopopov A, Winter SS, Larson RL, Borowitz MH, Silverman R, Chin L, Hunger SP, Jamieson C, Sallan SE, Look AT. Inactivation of LEF1 in T-cell acute lymphoblastic leukemia. Blood 115: 2845-2851, 2010. [Epub 2010 Feb 1]. PMID: 20124220
91. Harvey* RC, Mullighan*# CG, Chen I-M, Wharton W, Mikhail FM, Carroll AJ, Kang H, Liu W, Dobbin KK, Smith MA, Carroll WL, Devidas M, Bowman WP, Camitta B, Reaman GH, Hunger SP#, Downing JR, Willman CL#. Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, hispanic/latino ethnicity and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia. * RCH and CGM contributed equally; #CGM, SPH and CLW are corresponding authors. Blood, 115: 5312-5321, 2010. [Epub 2010 Feb 4]. PMID: 20139093
92. Pulsipher MA, Hunger SP, Gamis AS, Wall DA, Grupp SA. Allogeneic marrow transplantation in children with acute leukemia: Careful comparison to chemotherapy alternatives required. Leukemia, 24:1212-6. [Epub 2010 Apr 29]. PMID: 20428198
93. Jones AE, Albano EA, Lovell MP, Hunger SP. Metastatic alveolar rhabdomyosarcoma in multiple endocrine neoplasia type 2a. Pediatric Blood and Cancer, 55:1213-1216, 2010. [Epub 2010 Jun 8]. PMID: 20533522
94. Systematic review of the addition of vincristine plus steroid pulses in maintenance treatment for childhood acute lymphoblastic leukaemia – an individual patient data meta-analysis involving 5659 children. Childhood Acute Lymphoblastic Leukaemia Collaborative Group (CALLCG). British Journal of Haematology, 149:722-33, 2010. [Epub 2010 Mar 16]. PMID: 20331462
95. Maloney KW, Carroll WL, Carroll AJ, Devidas M, Borowitz MJ, Martin PL, Pullen J, Whitlock JA, Willman CL, Winick NJ, Camitta BM, Hunger SP. Down syndrome childhood acute lymphoblastic leukemia has a unique spectrum of sentinel cytogenetic lesions that influences treatment outcome: A report from the Children’s Oncology Group. Blood 116:1045-50, 2010. [Epub 2010 May 4]. PMID: 20442364
96. Cleaver AL, Beesley AH, Firth MJ, Sturges NC, O’Leary RA, Hunger SP, Baker DL, Kees UR. Gene-based outcome prediction in multiple cohorts of pediatric T-cell acute lymphoblastic leukemia: A Children’s Oncology Group study. Molecular Cancer, 9: 105, 2010. [Epub 2010 May 12]. PMID: 20459861
97. Gutierrez A, Dahlberg SE, Neuberg DS, Zhang J, Grebliunaite R, Sanda T, Protopopov A, Tosello V, Kutok J, Larson RS, Borowitz MJ, Loh ML, Ferrando AA, Winter SS, Mullighan CG, Silverman LB, Chin L, Hunger SP, Sallan SE, Look AT. Absence of biallelic TCRg deletions predicts early treatment failure in pediatric T-Cell acute lymphoblastic leukemia. Journal of Clinical Oncology, 28:3816-23, 2010. [Epub 2010 Jul 19]. PMID: 2064408.
98. Leclerc GJ, Sanderson C, Hunger S, Devidas M, Barredo JC. Folylpolyglutamate synthetase gene transcription is regulated by a multiprotein complex that binds the TEL-AML1 fusion in acute lymphoblastic leukemia. Leukemia Research 34: 1601-1609, 2010. [Epub 2010 Jun 8]. PMID: 20538338
99. Aricò M, Schrappe M, Hunger SP, Carroll WL, Conter V, Galimberti S, Manabe A, Saha V, Baruchel A, Vettenranta K, Horibe K, Benoit Y, Pieters R, Escherich G, Silverman LB, Pui CH, Valsecchi MG. Clinical outcome of 610 children with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia treated between 1995 and 2005. Journal of Clinical Oncology 28:4755-4761, 2010. [Epub 2010 Sep 27]. PMID: 20876426
100. Harvey RC, Mullighan CG, Wang X, Dobbin KK, Davidson GS, Bedrick EJ, Chen I-M, Atlas SR, Kang H, Ar K, Wilson CS, Wharton W, Murphy M, Devidas M, Carroll AJ, Borowitz MJ, Bowman WP, Downing JR, Relling M, Yang J, Bhojwani D, Carroll WL, Camitta B, Reaman GH, Smith M, Hunger SP, Willman CL. Identification of novel cluster groups in pediatric higher risk B-precursor acute lymphoblastic leukemia with gene expression profiling: Correlation with genome-wide DNA copy number alterations, clinical characteristics and outcome. Blood, 116: 4874-4884, 2010. [Epub 2010 Aug 10]. PMID: 20699438
101. Pieters R, Hunger SP, Boos J, Rizzari C, Silverman L, Baruchel A, Göekbuget N, Schrappe M, Pui C-H. L-asparaginase treatment in acute lymphoblastic leukemia: a focus on Erwinia asparaginase. Cancer, 117: 238-249, 2011 [Epub 2010 Sep 7]. PMID: 20824725
102. Caniza MA, Hunger SP, Schrauder A, Valsecchi MG, Pui C-H, Masera G, and members of the International Study Group of Childhood ALL (the “Ponte di Legno Working Group”). The controversy of varicella vaccination in children with acute lymphoblastic leukemia. Pediatric Blood and Cancer, 2010 Sep 16. [Epub ahead of print] PMID: 20848637.
103. Bowman WP, Larsen EL, Devidas M, Linda SB, Blach L, Carroll AJ, Carroll WL, Pullen DJ, Shuster J, Willman CL, Winick N, Camitta BM, Hunger SP, Borowitz MJ. Augmented therapy improves outcome for pediatric high risk acute lymphocytic leukemia: Results of Children’s Oncology Group trial P9906. Pediatric Blood and Cancer, 2011 Feb 25. doi: 10.1002/pbc.22944. [Epub ahead of print]
104. Hobernicht SL, Schweiger B, Zeitler P, Wang M, Hunger SP. Acquired growth hormone deficiency in a girl with chronic myelogenous leukemia treated with tyrosine kinase inhibitor therapy. Pediatric Blood and Cancer, 56: 671-673, 2011. [Epub 2010 Dec 22]. PMID: 2118203
105. Hunger SP, Raetz E, Loh M, Mullighan CG. Improving outcomes for high-risk ALL: Translating new discoveries into clinical care. Pediatric Blood and Cancer, 56: 984-993, 2011 [Epub 2011 Feb 15]. PMID: 21370430
106. Freyer DR, Devidas M, La M, Carroll WL, Gaynon PS, Hunger SP, Seibel NL. Post-relapse survival in childhood acute lymphoblastic leukemia is independent of initial treatment intensity: A report from the Children’s Oncology Group. Blood, 117: 3010-15, 2011 [Epub 2010 Dec 30]. PMID: 21193696
107. Yang JJ, Cheng C, Devidas M, Cao X, Fan Y, Campana D, Yang W, Neale G, Cox N, Scheet P, Borowitz MJ, Winick NJ, Martin PL, Willman CL, Bowman WP, Camitta BM, Carroll A, Reaman GH, Carroll WL, Loh M, Hunger SP, Pui C-H, Evans WE, Relling MV. Ancestry and pharmacogenomics of relapse in acute lymphoblastic leukemia. Nature Genetics, 43: 237-241, 2011 [Epub 2011 Feb 6]. PMID: 21297632
108. Yu L, Slovak, ML, Mannoor K, Chen C, Hunger SP, Carroll AJ, Schultz RA, Shaffer LG, Ballif BC, Ning Y. Microarray detection of multiple recurring submicroscopic chromosomal aberrations in pediatric T-cell acute lymphoblastic leukemia. Leukemia, 25: 1042-1046, 2011 [Epub 2011 Mar 8]. PMID: 21383747
109. Teuffel O, Kuster SP, Hunger SP, Conter V, Hitzler J, Ethier M-C, Shah PS, Beyene J, Sung L. Dexamethasone versus prednisone for induction therapy in childhood acute lymphoblastic leukemia: A systematic review and meta-analysis. Leukemia. 2011 Apr 29. [Epub ahead of print]. PMID: 21527934
110. Schafer ES, Hunger SP. Optimal therapy for acute lymphoblastic leukemia in adolescents and young adults. Nature Reviews Clinical Oncology, 8: 417-424, 2011 [Epub 2011 May 31]. PMID: 21629213.
111. Meng X, Matlawska-Wasowska K, Girodon F, Mazel T, Willman CL, Atlas S, Chen I-M, Harvey RC, Hunger SP, Ness SA, Winter SS, Wilson BS. GSI-I (Z-LLNle-CHO) inhibits gamma-secretase and the proteosome to trigger cell death in precursor-B acute lymphoblastic leukemia. Leukemia. 2011 Apr 15. [Epub ahead of print]. PMID: 21494254
112. Loudin MG, Wang J, Eastwood Leung HC, Gurusiddappa S, Meyer J, Condos G, Morrison D, Tsimelzon A, Devidas M, Heerema NA, Carroll AJ, Plon SE, Hunger SP, Basso G, Pession A, Bhojwani D, Carroll WL, Rabin KR. Genomic profiling in Down syndrome acute lymphoblastic leukemia identifies histone gene deletions associated with altered methylation profiles. Leukemia. 2011 Jun 7. [Epub ahead of print] PMID: 21647151
113. Matloub Y, Bostrom BC, Hunger SP, Stork LC, Angiolillo A, Sather H, La M, Gastier-Foster JM, Heerema NA, Sailer S, Buckley PJ, Thomson B, Cole C, Nachman JB, Reaman G, Winick NJ, Carroll WL, Devidas M, Gaynon PS. Escalating intravenous methotrexate improves event-free survival in children with standard-risk acute lymphoblastic leukemia: A report from the Children’s Oncology Group. Blood. 2011 May 11. [Epub ahead of print] PMID: 21562038
114. Zhang J*, Mullighan CG*, Harvey RC, Wu G, Chen X, Edmonson M, Buetow KE, Carroll WL, Chen I-M, Devidas M, Gerhard DS, Loh ML, Reaman GH, Relling MV, Camitta BM, Bowman WP, Smith M, Willman CL#, Downing JR#, Hunger SP#. Key pathways are frequently mutated in high risk childhood acute lymphoblastic leukemia: A report from the Children’s Oncology Group TARGET Project. JZ and CGM contributed equally. CLW, JRD and SPH contributed equally and are corresponding authors. Blood. 2011 Jun 16. [Epub ahead of print]
115. Gutierrez A, Kentsis A, Sanda T, Zhang J, Protopopov A, Chin L, Silverman LB, Winter SS, Hunger SP, Sallan SE, Zha S, Alt FW, Look AT. The BCL11B tumor suppressor is mutated in high-risk T-cell acute lymphoblastic leukemia. Blood, In Press.
Hunger SP, Lu X, Devidas M, Camitta BM, Gaynon PS, Winick NJ, Reaman GH, Carroll WL. Improved survival for children and adolescents with acute lymphoblastic leukemia from 1990-2005: A report from the Children’s Oncology Group. Submitted.
Hogan LE, Meyer JA, Yang J, Wang J, Wong N, Yang W, Condos N, Hunger SP, Raetz E, Saffery R, Relling M, Bhojwani D, Morrison DJ, Carroll WL. Integrated genomic analysis of relapsed childhood acute lymphoblastic leukemia reveals therapeutic strategies. Submitted.
Zhang J, Ding L, Holmfeldt L, Wu G, Heatley SL, Payne-Turner D, Collins-Underwood JR, Easton J, Chen X, Wang J, Rusch M, Ma J, Pounds SB, Wei L, Ulyanov A, Becksfort J, Gupta P, McGoldrick D, Zhao D, Alford D, Espy S, Bobba KC, Chen S-C, Song G, Pei D, Cheng C, Roberts S, Campana D, Coustan-Smith E, Shurtleff SA, Basso G, Hunger SP, Loh ML, Devidas M, Wood B, Winter S, Dunsmore SP, Lu C, Fulton RS, Fulton LF, Hong X, Harris CC, Dooling DJ, Ochoa K, Johnson K, Obenaur J, Pui C-H, Naeve C, Ley TJ, Mardis ER, Wilson RK, Downing JR, Mullighan CG. Discovery of novel recurrent mutations and rearrangements in early T-cell precursor acute lymphoblastic leukaemia by whole genome sequencing. Submitted.
Xu H, Cheng C, Devidas M, Pei D, Fan Y, Yang W, Neale G, Scheet G, Burchard EG, Torgerson DG, Eng C, Dean M, Antillon F, Winick NJ, Martin PL, Willman CL, Camitta BM, Reaman GH, Carroll WL, Loh ML, Evans WE, Pui C-H, Hunger SP, Relling MV, Yang JJ. ARID5B Genetic Polymorphisms Contribute to Racial Disparities in the Incidence and Treatment Oucome of Childhood Acute Lymphoblastic Leukemia. Submitted.
Morin RD*, Roberts KG*, Zhang J, Hirst M, Zhao Y, Su X, Harvey RC, Payne-Turner D, Chen X, Kasap C, Yan C, Churchman M, Becksfort J, Finney RP, Tse K, Moore R, Jones S, Edmonson MN, Hu Y, Buetow KE, Chen IM, Carroll WL, Larsen E, Devidas M, Gerhard DS, Wei L, Ma J, Reaman G, Smith M, Pui C-H, Downing JR, Willman CL, Loh M, Hunger SP#, Marra M#, Mullighan CG#. Novel Chromosomal Rearrangements In High-Risk Acute Lymphoblastic Leukemia. RD and KGR contributed equally. SPH, MM and CGM contributed equally and are corresponding authors. Submitted.
Mattano LA Jr, Devidas M, Nachman JB, La MK, Sather HN, Hunger SP, Steinherz PG, Gaynon PS, Seibel NL. Alternate-week dexamethasone to reduce ssteonecrosis risk in acute lymphoblastic leukemia: A report of the Children’s Oncology Group. Submitted.
Chang BH, Willi SG, Stork L, Hunger SP, Carroll WL, Camitta BM, Winick NJ, Druker BJ, Schultz KR. Imatinib resistant BCR-Abl mutations at relapse in children with Ph+ALL: a Children's Oncology Group (COG) study. Submitted.
Schrappe M, Hunger S, Pui C-H, Saha V, Gaynon P, Baruchel A, Masera G, Otten J, Tsuchida M, Versluys AB, Escherich G, Heymans M, Silverman L, Horibe K, Mann G, Camitta B, Harbott J, Riehm H, Richards S, Devidas M, Zimmermann M. Treatment outcome after remission induction failure in childhood acute lymphoblastic leukemia. Submitted.
Salzer WL, Jones TJ, Devidas M, Hilden JM, Winick N, Hunger S, Carroll WL, Camitta B, Dreyer ZD. Modifications to induction therapy decrease risk of early death in infants with acute lymphoblastic leukemia treated on Children’s Oncology Group P9407. Submitted.
Book Chapters, Commentaries and Review Articles
1. Hunger SP and Cleary ML: Chimaeric oncoproteins resulting from chromosomal translocations in acute lymphoblastic leukaemia. seminars in CANCER BIOLOGY 4: 387-399, 1993. PMID: 8142624
2. Hunger SP and Cleary, ML: PCR assessment of the efficacy of therapy in Philadelphia chromosome-positive leukemias. In: The Polymerase Chain Reaction. Mullis KB, Ferré F, and Gibbs RA, eds. Birkhäuser (Boston, MA), 1994.
3. Saltman DL, Hunger SP, and Turner GE: Molecular analysis of chromosome aberrations. Methods in Molecular Biology 29: 437-448, 1994. PMID: 8032421
4. Hunger SP: Cytogenetic and molecular abnormalities in lymphoid malignancies. In: Textbook of Malignant Haematology. Degos L, Linch DC, and Lowenberg B, eds. Martin Dunitz Ltd (London), 1999.
5. Hunger SP: Abnormal transcription factors produced by chromosome translocations in human cancer. In: Transcription Factors. Locker J, ed. BIOS Scientific Publishers Limited (Oxford), 2001.
6. Hunger SP: Why do some childhood ALLs relapse? Blood, 101: 3343, 2003.
7. Winick NJ, Carroll WL, Hunger SP: Childhood Leukemia: New Advances and New Challenges. New England Journal of Medicine 351: 601-603, 2004. PMID: 15295054
8. Slayton WB and Hunger SP: Cytogenetic and molecular abnormalities in lymphoid malignancies. In: Textbook of Malignant Hematology. Degos L, Linch DC, and Lowenberg B, eds. (pages 234-242) Taylor & Francis (London), 2005.
9. Hunger SP, Voss SD, Borowitz M. Detection of minimal residual disease in childhood cancers: technology and applications. ASCO Educational Book page 771-785, 2005.
10. Hunger SP, Biondi A. Early response and minimal residual disease testing in childhood ALL: Methodologies and clinical application. Educational Book, International Society of Paediatric Oncology, 2005, page 70-73.
11. Carroll WC, Raetz E, Loh M, Hunger S, Schultz K. Current biological basis for risk stratification in Children’s Oncology Group (COG) acute lymphoblastic leukemia trials. Educational Book, International Society of Paediatric Oncology, 2006.
12. Graham DK and Hunger SP: BAC to the Future? Comparative genomic hybridization and genotyping pediatric leukemia cytogenetic abnormalities. Pediatr Blood Cancer 51: 153-154. Epub 2008 Feb 25. PMID: 18300321
13. Brown P and Hunger SP: Acute leukemia in children. In: Conn’s Current Therapy 2010. Bope ET Rakel RE and Kellerman RD, eds. Elsevier, 2009.
14. Gore L and Hunger SP. Molecular oncology and translational therapy. In Cancer in Children and Adolescents. Carroll WL and Findlay JL, eds. Jones and Bartlett Publishers (Sudbury Mass), 2010.
15. Brown P, Hunger SP, Smith FO, Carroll WL, Reaman GH. Novel targeted drug therapies for the treatment of childhood acute leukemia. Expert Review of Hematology, 2: 145-158, 2009. PMID: 20126514
16. Macy M, Hunger SP. F1000 Medicine review of Testicular function of survivors of childhood cancer: a comparative study between ifosfamide- and cyclophosphamide-based regimens. Faculty of 1000 Medicine, 25 Mar 2009.
17. Macy M, Hunger SP. F1000 Medicine review of Potentiating effects of RAD001 (Everolimus) on vincristine therapy in childhood acute lymphoblastic leukemia. Faculty of 1000 Medicine, 21 May 2009.
18. Macy M, Hunger SP. F1000 Medicine review of Methotrexate/6-mercaptopurine maintenance therapy influences the risk of a second malignant neoplasm after childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study. Faculty of 1000 Medicine, 28 Sep 2009.
19. Macy M, Hunger SP. F1000 Medicine review of Comparison of neurocognitive functioning in children previously randomly assigned to intrathecal methotrexate compared with triple intrathecal therapy for the treatment of childhood acute lymphoblastic leukemia. Faculty of 1000 Medicine, 13 Jan 2010.
20. Schrappe M, Nachman J, Hunger S, Schmiegeloew K, Conter V, Masera G, Pieters R, Pui CH. Educational symposium on long-term results of large prospective clinical trials for childhood acute lymphoblastic leukemia (1985-2000). Leukemia, 24: 253-254, 2010. PMID: 20145664
21. Prima V, Glushakova LG, Hunger SP. MEF2D (myocyte enhancer factor 2D). Atlas Genet Cytogenet Oncol Haematol. October 2009. URL :
22. Mullighan CG, Pui, C-H, Hunger SP. Advances in understanding the genetics and improvements in treatment for adolescents and young adults with acute lymphoblastic leukemia. ASCO Educational Book 2010, pages 383-389.
23. Hunger SP, Conter V, Raetz EA, Valsecchi MG, Henze G. Classification And Treatment Of Acute Lymphoblastic Leukemia. In Childhood Leukemia. Reaman GH and Smith FO, eds. Springer, 2010.
24. Mullighan CG, Hunger SP, Meshinchi S. Molecular genetics in children, adolescents and young adults with acute lymphoblastic leukemia and acute myeloid leukemia. In Hematological Malignancies in Children, Adolescents and Young Adults. Cairo MS and Perkins S, eds. World Scientific Press, In Press.
25. Hunger SP. SIOP state-of-the-art acute lymphoblastic leukemia symposium: Philadelphia chromosome positive ALL: Use of tyrosine kinase inhibitors. Educational Book, International Society of Paediatric Oncology, 2010, page 67-71.
26. Macy M, Hunger SP. F1000 Medicine review of Phase I Study of Bortezomib Combined with Chemotherapy in Children with Relapsed Childhood Acute Lymphoblastic Leukemia (ALL): A Report From the Therapeutic Advances in Childhood Leukemia (TACL) Consortium. Faculty of 1000 Medicine, 27 July 2010.
27. Macy M, Hunger SP. F1000 Medicine review of Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high risk acute lymphoblastic leukaemia: Long-term follow-up of a prospective, randomised, multicentre trial. Faculty of 1000 Medicine, 13 January 2011.
28. Eisenman K, Hunger SP. F1000 Medicine review of Late Recurrence of Childhood T-Cell Acute Lymphoblastic Leukemia Frequently Represents a Second Leukemia Rather Than a Relapse: First Evidence for Genetic Predisposition. Faculty of 1000 Medicine, 17 March 2011.
29. Rogers A, Hunger SP. F1000 Medicine review of Pharmacokinetic, pharmacodynamic, and pharmacogenetic determinants of osteonecrosis in children with acute lymphoblastic leukemia. Faculty of 1000 Medicine, 20 May 2011.
30. Rogers A, Hunger SP. F1000 Medicine review of Superior outcome of pediatric acute myeloid leukemia patients with orbital and CNS myeloid sarcoma: A report from the Children's Oncology Group. Faculty of 1000 Medicine, 20 May 2011.
31. Hunger SP. First And Second Generation Tyrosine Kinase Inhibitors For BCR-ABL1-Rearranged Pediatric ALL. ASH Education Book 2011. In Press.
Abstracts
1. Hunger SP, Amylon MD, Donlon TA, and Cleary ML: Longitudinal monitoring of minimal residual disease by PCR in a patient with Philadelphia chromosome positive ALL. Blood 78:443a, 1991.
2. Hunger SP, Ohyashiki K, and Cleary ML: The t(17;19)(q21;p13) in ALL fuses the E2A gene with the gene for a novel chromosome 17 transcription factor. Proc. Amer. Assoc Cancer Res. 33:397, 1992 (Poster session).
3. Hunger SP and Cleary ML: The t(17;19) derived chimeric protein E2A-HLF displays dominant negative transcriptional regulatory properties. Blood 80:153a, 1992 (Oral presentation).
4. Hunger SP, Link MP, and Donaldson SS: Long-term results of ABVD/MOPP and low dose involved field radiotherapy in Pediatric Hodgkin’s disease: The Stanford experience. Proc. Amer. Soc. Clin. Oncol. 12: 384, 1993 (Oral presentation).
5. Hunger SP and Cleary ML: DNA binding and transcriptional regulatory properties of E2A-HLF diverge from those of wild type HLF. Blood 82:324a, 1993 (Oral presentation).
6. Jurema M, Hunger SP, Negrin R, and Cleary ML: Assessment of minimal residual disease (MRD) in autologous peripheral blood stem cell (PBSC) transplantation for multiple myeloma (MM). Blood 82:431a, 1993 (Poster session).
7. Hunger SP, Li S, Fall MZ, Naumovski L, Cleary ML: Delineation of a highly conserved transcriptional activation domain (TAD) in HLF and TEF. Blood 86: 429a, 1995 (Oral presentation).
8. Maloney KW, Rubnitz JE, Cleary ML, Frankel LS, Hakami N, Link MP, Pullen DJ, Hunger SP: Lack of ETV6 (TEL) gene rearrangements in infant acute lymphoblastic leukemia. Blood, 88: 72a, 1996 (Poster session).
9. Maloney KW, Rubnitz JE, Cleary ML, Frankel LS, Hakami N, Link MP, Pullen DJ, Hunger SP: Lack of homozygous p16INK4A (p16) or p15INK4B (p15) gene deletions in infant acute lymphoblastic leukemia (ALL). Proc. Amer. Soc. Clin. Oncol. 16: 514a, 1997 (Oral presentation).
10. Nuss R, Sifontes MT, Hunger SP, Waters JL, Jacobson LJ, Manco-Johnson MJ: Activated protein C resistance and the factor V Leiden mutation in children with thrombosis. Congress of the International Society on Thrombosis and Haemostasis, 1997 (Poster session).
11. Manco-Johnson MJ, Sifontes MT, Nuss R, Hunger SP, Jacobson LJ, Waters JL: Correlation between the functional assay for activated protein C resistance and Factor V Leiden in the neonate and relationaship to ethnicity and family history of thrombosis. Congress of the International Society on Thrombosis and Haemostasis, 1997 (Oral presentation).
12. Hunger SP, Fall MZ, Camitta BM, Carroll AJ, Link MP, Lauer SJ, Mahoney DH, Pullen DJ, Shuster JJ, Steuber CP, Cleary ML: E2A-PBX1 chimeric transcript status at end of consolidation is not predictive of treatment outcome in childhood acute lymphoblastic leukemias with a t(1;19)(q23;p13): A Pediatric Oncology Group study. Blood, 90: 423a, 1997 (Oral presentation).
13. Hunger SP, Silliman CC, Wei Q, McGavran L. Multiple different isoforms of AF10-CALM and CALM-AF10 cDNAs are generated by the t(10;11)(p13-14;q14-21) in T-cell ALL. Blood, 90: 318a, 1997 (Poster session).
14. Maloney KW, Odom LF, McGavran L, Hunger SP. Acquisition of homozygous p16INK4A and p15INK4B deletions between initial diagnosis and relapse in children with acute lymphoblastic leukemia. Blood, 90: 218b, 1997 (Poster session).
15. Maloney KW, McGavran L, Odom LF, Hunger SP. Homozygous p16INK4A and p15INK4B deletions in childhood acute lymphoblastic leukemias containing E2A translocations. Blood, 90: 186a, 1997 (Poster session).
16. Maloney KW, Murphy J, Odom LF, Stork L, Wei Q, Hunger SP: TEL-AML1 fusion identifies a subset of children with NCI standard risk acute lymphoblastic leukemia who have an excellent prognosis when treated with a single delayed intensification. Blood 92:1616, 1998 (Poster session).
17. Manco-Johnson M, Sifontes M, Nuss R, Hunger S, Loutzenhiser J, Jacobson L, Drose J, Manco-Johnson M. Coagulation abnormalities in neonatal catheter-related thromboses. Presented at the XVIIth Congress International Society for Thrombosis and Hemostasis, 1999 (Oral presentation).
18. Greffe BS, Stork L, Albano E, Odom S, Hunger SP. Pulmonary parenchymal Hodgkin's disease at diagnosis: A 10 year single institution experience. Medical & Pediatric Oncology 33: 287, 1999 (Poster session).
19. Moos PJ, Bruggers CS, Smith F, Liu T, Hunger SP, Gaynon P, Carroll WL. Gene expression profiling of childhood leukemia. Blood 94: 498a, 1999 (Poster session).
20. Giller RH, Quinones RR, Shpall EJ, Prothe K, Schissel D, Rottman S, Pasut B, Foreman N, Hunger SP. Promising outcomes of allogeneic cord blood transplant for high risk acute lymphoblastic leukemia in children. American Society of Pediatric Hematology Oncology, 2000 (Poster session).
21. Hunger SP, Boomer T, McGavran L, Meltesen L, Olsen AS, Hunger SP. FISH Detection of E2A translocations in ALL. Blood 96: 463a, 2000 (Oral presentation).
22. Meech S, Gump J, McGavran L, Meltesen L, Odom LF, Wei Q, Hunger SP. Tropomyosin 4 is fused to ALK in an unusual childhood ALCL with the immunophenotype and functional properties of a natural kill cell malignancy. Blood 96: 85a (Poster session).
23. Meltesen L, Liang X, Meech S, Hutchinson R, Bitter MA, Ryder J, Hunger S, Lovell M, Wei Q, Odom L, McGavran L. FISH studies of anaplastic large cell lymphoma in children: Improved diagnosis and unexpected anaplastic lymphoma kinase gene variant rearrangements. Blood 96: 160b, 2000 (abstr.).
24. Moos PJ, Raetz EA, Carlson MA, Smith FE, Hunger SP, Wei Q, Carroll WL. Identification of candidate genes to augment current classification schemes in pediatric acute leukemia. Blood 96: 463a, 2000 (Oral presentation).
25. Hollander MC, Salvador JM, Hunger SP, Molinaro TE, Anver MR, Fornace AJ. Gadd45a acts as a modifier locus for lymphoblastic lymphoma formation in mice. AACR Meeting on Mouse Models of Cancer 11/2000.
26. Monroe T, Gump J, Wei Q, Ess J, Carroll AJ, Hunger SP. Molecular analysis of MLL-AF10, CALM-AF10 AND AF10-CALM fusion transcripts in pediatric leukemias with a t(10;11). WSPR, 2001 (Oral presentation).
27. Quinones R, Hunger S, Foreman N, Shpall E, Prothe K, Schissel D, Hild E, Malcolm J, Rottman S, Pasut B, Peltz A, McNiece I, Giller R. Successful reprioritization to unrelated cord blood for hematopoietic stem cell transplantation (HSCT) in children and adolescents with leukemia. American Society of Blood and Marrow Transplantation; Keystone, CO; February 2001.
28. Gore L, Hunger SP, Wei Q, Giller RH, Sievers E, McGavran L, Quinones RR. 2001. Remission re-induction with enhancement of graft-versus-host disease by gemtuzumab ozogamycin in acute lymphoblastic leukemia with myeloid antigen expression. Submitted to ASBMT 2002.
29. Giller RH, Trobaugh AD, Hunger SP, Malcolm J, Schissel D, Hild E, Quinones RR. Acute myeloid leukemia and myelodysplastic syndrome associated with monosomy 7: Management by alogeneic hematopoietic stem cell transplantation. Submitted to ASPHO 2002.
30. Hunger SP, Zhong C. Cryptic t(12;19) in ALL with lineage switch to AML creates two new E2A fusion proteins. Blood 100: 529a, 2002 (Poster session).
31. Dharnidharka VS, Douglas VK, Hunger SP, Fennell RS. Hodgkin’s disease after post-transplant lymphoproliferative disorder in a renal transplant recipient. 2nd Congress of the International Pediatric Transplant Association, April 2003.
32. Prima V, Rice A, Zhong C, Hunger SP. Variant t(1;19)(q23;p13) in childhood acute lymphoblastic leukemia (ALL) fuses MEF2D and DAZ-AP1. Pediatrics Science Day; University of Florida College of Medicine, Gainesville FL March 13, 2003 (Oral Presentation).
33. Dharnidharka VS, Douglas VK, Hunger SP, Fennell RS. Hodgkin’s disease after post-transplant lymphoproliferative disorder in a renal transplant recipient. 2nd Congress of the International Pediatric Transplant Association, April 2003. (Oral Presentation).
34. Prima V, Hunger SP. Functional implications of MEF2D-DAZAP1 fusion in a childhood acute lymphoblastic leukemia (ALL) with variant t(1;19)(q23;p13). Pediatric Science Day; University of Florida College of Medicine, Gainesville FL April 8, 2004 (Poster session).
35. Jackman K, Hunger SP. A preclinical study of flavopiridol in the treatment of relapsed pediatric acute lymphoblastic leukemia. Pediatric Science Day; University of Florida College of Medicine, Gainesville FL April 8, 2004 (Poster session).
36. Prima V, Hunger SP. Functional implications of MEF2D-DAZAP1 fusion in childhood acute lymphoblastic leukemia (ALL) with variant t(1;19)(q23;p13). University of Florida College of Medicine Research Day, April 27, 2004 (Poster session).
37. Zhou M, Frye C, Hunger SP. Asparagine synthetase(AS) plays an important role in determining the response to Asparaginase (Asp) treatment in acute lymphoblastic leukemia (ALL) cells April 27, 2004. University of Florida College of Medicine Research Day, April 27, 2004 (Poster session).
38. Prima V, Gore L, Caires A, Boomer T, Yoshinari T, Masue I, Varella-Garcia M, Hunger SP. Chimeric MEF2D and DAZAP1 fusion proteins are created by a variant t(1;19)(q23;p13.3) in acute lymphoblastic leukemia. Blood 104: 159a, 2004 (Oral presentation).
39. Borowitz MJ, Devidas M, Hunger SP, Carroll W, Raetz E. Minimal residual disease in childhood acute lymphoblastic leukemia in relapse. A Children’s Oncology Group study. Blood 104: 96a, 2004 (Oral presentation).
40. Zhou M, Hunger SP. Multiple methods of determination of asparagine synthetase (AS) expression in leukemia cells. Joint Cancer Conference of the Florida Universities; Orlando FL; January 27, 2005 (oral presentation).
41. Prima V, Hunger SP. Chimeric MEF2D and DAZAP1 fusion proteins are created by a variant t(1;19)(q23;p13.3) in acute lymphoblastic leukemia (ALL). Pediatric Science Day; University of Florida College of Medicine, Gainesville FL, March 10, 2005 (Poster session).
42. Jackman K, Hunger SP. Flavopiridol combined with paclitaxel could offer a new treatment regimen for relapsed childhood ALL. Pediatric Science Day; University of Florida College of Medicine, Gainesville FL, March 10, 2005 (Oral presentation).
43. Zhou M, Harvey RC, Hunger SP. Asparagine synthetase RNA and protein expression in acute lymphoblastic leukemia cell lines and patient samples. 2005 ASCO Annual Meetings Proceedings 23: 802s, 2005 (Oral presentation).
44. Jackman K, Hunger SP. Preclinical studies of flavopiridol (FP) in childhood acute lymphoblastic leukemia. Blood 106: 188b, 2005.
45. Bhojwani D, Raetz E, Moskowitz N, Lee H, Sohn B, Hunger SP, Carroll WL. Gene pathways that distinguish diagnosis and relapse in childhood acute lymphoblastic leukemia (ALL). Blood 106: 250a, 2005 (Poster presentation).
46. Wetzler M, Brady MT, Siat SJN, Kakati S, Block AM, Wang X, Hunger SP, Carroll AJ, Ferrone S. Differential antigenic profile of high molecular weight-melanoma associated antigen (HMW-MAA) expressed by 11q23-positive acute leukemia: An immunotherapeutic target. Blood 106: 911a, 2005 (Poster presentation).
47. Moskowitz N, Bhojwani D, Kang H, Min DJ, Potter J, Harvey R, Seibel N, Raetz E, Sather H, Hunger S, Willman C, Carroll WL. Gene signatures predictive of outcome in higher risk childhood acute lymphoblastic leukemia (ALL). Blood 106: 418a, 2005 (Poster presentation).
48. Staba SL, Hunger SP, Wingard JR. “Mini” Methotrexate and FK506 as GVHD Prophylaxis in Pediatric Umbilical Cord Blood Transplantation. CIBMTR/ASBMT Tandem meeting, Honolulu, Hawaii February 2006. (poster)
49. Heerema NA, Gastier-Foster J, Chen IM, Harvey RC, Raetz EA, Loh ML, Hunger SP, Winick NJ, Carroll WL, Carroll AJ. Risk Stratification in Children’s Oncology Group (COG) B-Cell Precursor Acute Lymphoblastic Leukemia (B-ALL): Interactions of Cytogenetic and Molecular Approaches. Submitted for American Cytogenetics Conference Annual Meeting.
50. Jackman K, Hunger SP. Flavopiridol (FP) Combined with Paclitaxel (PAC) Could Offer a New Treatment Regimen for Acute Lymphoblastic Leukemia (ALL)
51. Prima V, Hunger SP. Rearranged MEF2D and DAZAP1 functional domains exhibit transforming properties in the variant t(1;19)(q23;p13) reciprocal translocation products. Florida Genetics Conference, University of Florida, Gainesville FL.
52. Borowitz MJ, Devidas M, Bowman WP, Carroll WL, Chen I, Harvey R, Hunger SP, Martin PJ, Pullen J, Viswanatha D, Willman CL, Winick N, Camitta B. Prognostic significance of minimal residual disease (MRD) in childhood B-precurosor ALL and it relation to other risk factors. A Children’s Oncology Group (COG) Study. Blood 108: 69a, 2006 (Oral presentation).
53. Dunsmore K, Devidas M, Borowitz MJ, Winick N, Hunger S, Carroll WL, Camitta B. Nelarabine can be safely integrated into an intensive, multiagent chemotherapy regimen for the treatment of T-cell acute lymphoblastic leukemia in children: A report of the Children’s Oncology Group AALL00P2 protocol for T-cell leukemia. Blood 108: 528a, 2006 (Poster presentation).
54. Maloney K, Larsen E, Mattano L, Friedmann A, Devidas M, Hunger S, Winick N, Carroll WL. Increased infection-related mortality for children with Down syndrome (DS) in contemporary Children’s Oncology Group (COG) acute lymphoblastic leukemia (ALL) clinical trials. Blood 108: 529a, 2006 (Poster presentation).
55. Matloub Y, Angiolillo A, Bostrom B, Hunger SP, Nachman J, Sather H, Carroll WL, Winick N, Gaynon PS. Double delayed intensification (DDI) is equivalent to single DI (SDI) in children with National Cancer Institute (NCI) standard-risk acute lymphoblastic leukemia (SR-ALL) treated on Children’s Cancer Group (CCG) clinical trial 1991 (CCG-1991). Blood 108: 47a, 2006 (Oral presentation).
56. Nguyen K, Cheng S-C, La M, Raetz E, Sather S, Carroll WL, Winick N, Hunger SP, Gaynon P, Loh M. Factors influencing survival after relapse from childhood ALL: A legacy CCG study. Blood 108: 525a, 2006 (Poster presentation).
57. Raetz EA, Borowitz MJ, Devidas M, Hunger SP, Winick N, Camitta B, Gaynon PS, Carroll WL. Outcomes of Children with First Marrow Relapse: Results from Children[pic]s Oncology Group (COG) Study AALL01P2. Blood 108: 530a, 2006 (Poster presentation).
58. Rubnitz J, Wichlan D, Devidas M, Shuster J, Kurtzberg J, Bell B, Hunger S, Chauvent A, Pui C-H, Camitta B, Pullen J. Prospective analysis of TEL and MLL gene rearrangements in childhood acute lymphoblastic leukemia: a Children’s Oncology Group study. Blood 108: 68a, 2006 (Oral presentation).
59. Schultz KR, Aledo A, Bowman P, Slayton W, Willman C, Gastier-Foster J, Heerema N, Carroll A, Sather H, Winick N, Hunger S, Carroll W. Minimal toxicity of imatinib mesylate In combination with intensive chemotherapy for Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL) In children: A report of the Children’s Oncology Group (COG) AALL0031 protocol for very high risk ALL. Blood 108: 87a, 2006 (Oral presentation).
60. Winick N, Borowitz MJ, Devidas M, Martin P, Pullen J, Hunger SP, Carroll WL, Camitta B. Changes in the delivery of standard chemotherapeutic agents during induction affect early measures of minimal residual disease (MRD): POG 9900 for patients with B-precursor low and standard risk ALL. Blood 108: 643a, 2006 (Poster presentation).
61. Dharnidharka VR, Hunger SP, Yang F, Braylan RC, Fennell RS. Unusual localization of post-transplant lymphoproliferative disease (PTLD) to the tongue. Pediatric Transplantation 11: S1, 110, 2007 (Poster presentation).
62. Hunger SP, Yang F, Li Y, Braylan R, Yang L-J. T-cell post-transplant lymphoproliferative disorder (PTLD) in children. Pediatric Transplantation 11: S1, 120, 2007 (Poster presentation).
63. Araya C, Fennell RS, Gonzalze-Peralta RP, Hunger SP, Dharnidharka VR. Native kidney post-transplant lymphoproliferative disease in a non-renal transplant patient. Pediatric Transplantation 11: S1, 246, 2007 (Poster presentation).
64. Narendran A, Gore L, Bagatell R, Whitlock J, Kersey J, Boklan J, Katzenstein H, Hunger S, Amid A, Booth K, Herzog C, Arceci R, Trippett T. An experimental model for target modulation analysis in early
clinical trials: Effects on Hsp90 client proteins in cells of patients
treated with 17-AAG. Pediatric Blood Cancer 48: 636, 2007 (poster presentation).
65. Matloub Y, Angiolillo A, Bostrom B, Stork L, Hunger SP, Nachman J, Sather H, La M, Carroll WL, Gaynon PS. Augmented Berlin-Frankfurt-Muenster (ABFM) regimen for children with standard-risk acute lymphoblastic leukemia (SR-ALL) and slow early response (SER). Journal of Clinical Oncology 25: 528s, 2007 (Oral presentation).
66. Gore L, Kuttesch J, Hunger SP, Herzog C, Narendaren A, Boklan J, Foreman NK, Ivy SP, Boucher N, Trippett TM. A phase Ib study of oxaliplatin in combination with fluorouracil (5FU) and leucovorin (LV) in pediatric patients (pts) with advanced solid tumors. Journal of Clinical Oncology 25: 538s, 2007 (Poster presentation).
67. Trippett T, Kuttesch J, Herzog C, Boklan J, Bagatell R, Hunger S, Arceci R, Lu H, Langer C, Gore L. A phase I study of cetuximab and irinotecan in pediatric patients with refractory solid tumors. Journal of Clinical Oncology 25: 537s, 2007 (Poster presentation).
68. Yang J, Cheng C, Yang W, Trevino L, Fan Y, Pounds S, French D, Shimasaki N, Campana D, Downing J, Evans W, Pui C-H, Devidas M, Bowman WP, Camitta B, Willman C, Borowitz M, Carroll W, Hunger S, Relling M. Genome-wide germline variation and treatment response in acute lymphoblastic leukemia. Submitted for Annual Meeting of the American Society of Human Genetics, 2007.
69. Harvey RC, Davidson GS, Wang X, Dobbin KK, Bedrick EJ, Wilson CS, Atlas SR, Kang H, Chen I-M, Hunger SP, Devidas M, Borowitz MJ, Bowman P, Carroll WL, Camitta B, Reaman GH, Willman CL. Expression profiling identifies novel genetic subgroups with distinct clinical features and outcome in high-risk pediatric precursor B acute lymphoblastic leukemia (B-ALL). A Children’s Oncology Group study. Blood (ASH Annual Meeting Abstracts), 110: 1430, 2007 (Poster presentation).
70. Gaynon PS, Camitta BC, Matloub Y, Martin PL, Winick N, Seibel NL, Bowman WP, Sather HN, Devidas M, Hunger S, Carroll WL. Outcomes for B-precursor patients in legacy Children’s Cancer Group (CCG) and Pediatric Oncology Group (POG) studies in childhood acute lymphoblastic leukemia (ALL): A Children's Oncology Group (COG) report. Blood (ASH Annual Meeting Abstracts), 110: 847. 2007 (Poster presentation).
71. Kang H, Bedrick EJ, Chen I-M, Wilson CS, Atlas SR, Harvey RC, Hunger SP, Devidas M, Borowitz MJ, Bowman P, Carroll WL, Camitta B, Reaman GH, Willman CL. Molecular classifiers for prediction of minimal residual disease (MRD) and event free survival (EFS) improve risk assignment at diagnosis in pediatric high-risk B precursor acute lymphoblastic leukemia (ALL): A Children’s Oncology Group study. Blood (ASH Annual Meeting Abstracts) 110: 1422, 2007 (Poster presentation).
72. Loh ML, Raetz E, Devidas M, Linda SB, Borowitz MJ, Carroll AJ, Chen I-ML, Gastier-Foster JM, Heerema NA, Harvey RC, Larsen E, Maloney K, Willman CL, Winick N, Wood B, Hunger SP, Carroll WL. Early response to therapy is significantly associated with genetic subtype of acute lymphoblastic leukemia: A report from the Children’s Oncology Group. Blood (ASH Annual Meeting Abstracts), 110: 758. 2007 (Oral presentation).
73. Mullighan CG, Su X, Ma J, Yang W, Relling MV, Carroll WL, Reaman G, Bowman P, Devidas M, Hunger SP, Downing JR. Genome-wide profiling of high-risk pediatric acute lymphoblastic leukemia (ALL): The ALL pilot project for the Therapeutically Applicable Research To Generate Effective Treatments (TARGET) initiative. Blood (ASH Annual Meeting Abstracts) 110: 229, 2007 (Oral presentation).
74. Schultz KR, Bowman WP, Slayton W, Aledo A, Devidas M, Sather H, Borowitz MJ, Davies SM, Trigg M, Pasut B, Jorstad D, Eslinger T, Burden LE, Wang C, Rutledge R, Gaynon PS, Carroll AJ, Heerema NA, Winick N, Hunger S, Carroll WL, Camitta B. Improved early event free survival (EFS) in children with Philadelphia chromosome−positive (Ph+) acute lymphoblastic leukemia (ALL) with intensive imatinib in combination with high dose chemotherapy: Children's Oncology Group (COG) study AALL0031. Blood (ASH Annual Meeting Abstracts), 110: 4, 2007 (Plenary Session presentation).
75. Trevino LR, Yang W, Hunger S, Carroll WL, Devidas M, Willman CL, Downing J, Evans WE, Pui C-H, Relling MV. Children with t(12;21)/TEL-AML1-positive acute lymphoblastic leukemia exhibit a distinct germline genomic signature. Blood (ASH Annual Meeting Abstracts), 110: 760, 2007 (Oral presentation).
76. Winick N, Martin PL, Devidas M, Shuster J, Borowitz MJ, Bowman P, Larsen E, Pullen J, Hunger SP, Carroll WL, Camitta BM. Delayed intensification (DI) enhances event-free survival (EFS) of children with B-precursor acute lymphoblastic leukemia (ALL) who received intensification therapy with six courses of intravenous methotrexate (MTX): POG 9904/9905: A Children’s Oncology Group study (COG). Blood (ASH Annual Meeting Abstracts) 110: 583, 2007 (Oral presentation).
77. Yang J, Bhojwani D, Yang W, Fan Y, Devidas M, Hunger S, Willman C, Raetz E, Relling MV, Carroll WL. Genome-wide profiling reveals recurring molecular defects in relapsed childhood acute lymphoblastic leukemia (ALL): A Children’s Oncology Group study. Blood (ASH Annual Meeting Abstracts) 110: 72, 2007 (Oral presentation).
78. Dreyer ZE, Dinndorf P, Hilden JM, Steuber CP, La M, Winick N, Carroll WL, Hunger SP, Camitta B. Unexpected toxicity with intensified induction in infant acute lymphoid leukemia.
Blood (ASH Annual Meeting Abstracts) 110: 852, 2007 (Poster presentation).
79. Carroll WL, Hunger SP, Borowitz MJ, Bhojwani D, Willman CL, Devidas M, Schultz K, Loh ML, Raetz EA. Risk-adapted therapy for children with acute lymphoblastic leukemia (ALL): the Children’s Oncology Group (COG) approach. Acute Leukemias XII, February 16 - 20, 2008, Munich, Germany.
80. Maloney K, Larsen E, Mattano L, Friedmann A, Devidas M, Sather H, Hunger S, Winick N, Carroll WL. Improvement in the infection-related mortality for children with Down Syndrome (DS) in contemporary Children’s Oncology Group (COG) acute lymphoblastic leukemia (ALL) clinical trials. Selected for Oral Presentation at ASPHO 2008.
81. Martin PL, Winick N, Devidas M, Shuster J, Borowitz MJ, Bowman P, Larsen E, Pullen DJ, Hunger SP, Carroll WL, Camitta B. Outcomes With 4hr vs 24hr IV Methotrexate (MTX) Infusions During Intensification Therapy for Childhood ALL: POG 9904/9905: A Children’s Oncology Group Study (COG). Selected for Oral Presentation at ASPHO 2008.
82. Borowitz M, Devidas M, Hunger S, Carroll W, Linda S, Pullen J, Viswanatha D, Willman C, Winick N, Camitta B. Prognostic significance of end consolidation minimal residual disease (MRD) in childhood acute lymphoblastic leukemia (ALL): A report from the Children’s Oncology Group (COG). Journal of Clinical Oncology (2008 ASCO Annual Meeting Proceedings) 26: 539s (abstract #10000), 2008 (Oral presentation).
83. Dunsmore KP, Devidas M, Borowitz MJ, Winick N, Hunger SP, Carroll WL, Camitta BM. Nelarabine in combination with intensive modified BFM AALL00P2. A pilot study for the treatment of high risk T-ALL A report from the Children’s Oncology Group. Selected for Oral Presentation at ASCO 2008. Journal of Clinical Oncology (2008 ASCO Annual Meeting Proceedings) 26: 539s (abstract #10002), 2008 (Oral presentation).
84. Maloney K, Carroll WL, Carroll A, Devidas M, Hunger SP, Martin PL, Willman C, Winick N, Whitlock J, Camitta B. The biology of Down Syndrome (DS) acute lymphoblastic leukemia (ALL) differs from that of non-DS ALL: Children’s Oncology Group (COG) study P9900. Selected for Oral Presentation at ASCO 2008. Journal of Clinical Oncology (2008 ASCO Annual Meeting Proceedings) 26: 539s (abstract #10003), 2008 (Oral presentation).
85. Hunger S, Devidas M, Camitta B, Gaynon P, Winick N, Reaman G, Carroll W. Improved survival for children with acute lymphoblastic leukemia (ALL) from 1990-2005: A report from the Children’s Oncology Group. 40th Congress of the International Society of Pediatric Oncology. Berlin, Germany Abstract O.048 page 31 (Oral presentation), 2008.
86. Hunger S, Carroll W, Devidas M, Mullighan M, Downing J, Willman C, Relling M, Chen I-M, Harvey R, Reaman G. Intramural and extramural NCI collaboration: The childhood ALL TARGET project. 40th Congress of the International Society of Pediatric Oncology. Berlin, Germany Abstract S.017 page 6 (Oral presentation), 2008.
87. Aricò M, Schrappe M, Hunger SP, Carroll WL, Conter V, Di Lorenzo P, Manabe A, Saha V, Baruchel A, Vettenranta K, Tsuchida M, Benoit Y, Pieters R, Escherich G, Silverman LB, Pui C-H, Valsecchi M. Clinical outcome of 640 children with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia treated between 1995 and 2005. Blood (ASH Annual Meeting Abstracts), Nov 2008; 112: 568 (Oral presentation).
88. Bhatia S, Villaluna D, Landier W, Schaible A, Hageman L, Hanby C, Leisenring W, Hunger SP, Robison LL, Relling MV, Wong FL. Prevalence and predictors of non-adherence to 6-Mercaptopurine (6MP) in children with acute lymphoblastic leukemia (ALL) - a Children’s Oncology Group Study. Blood (ASH Annual Meeting Abstracts), Nov 2008; 112: 89 (Poster presentation).
89. Bhojwani D, Wang J, Yang JJ, Morrison D, Devidas M, Raetz EA, Hunger SP, Relling MV, Carroll WL. Evolution of gene expression signatures in relapsed childhood acute lymphoblastic leukemia differ based on timing of relapse. Blood (ASH Annual Meeting Abstracts), Nov 2008; 112: 3345 (Poster presentation).
90. Czuchlewski DR, Harvey RC, Chen I-M, Bourguet-Vincent A, Rodgers B, Vestal R, Ar K, Kang H, Wilson CS, Larsen E, Hunger SP, Loh M, Devidas M, Raetz E, Reaman G, Carroll WL, Winick N, Willman CL. Quantitative RT-PCR for expression of a small subset of genes identifies novel prognostic subgroups in high-risk pediatric precursor B-cell acute lymphoblastic leukemia (HR-ALL): Clinical applicability of gene expression microarray data from Children’s Oncology Group trials. Blood (ASH Annual Meeting Abstracts), Nov 2008; 112: 1514 (Poster presentation).
91. Freyer DR, Seibel NL, La MK, Devidas M, Carroll WL, Hunger SP, Gaynon PS. Survival after relapse in higher risk acute lymphoblastic leukemia (ALL) in children and adolescents is independent of prior treatment intensity: A report from the Children’s Oncology Group (COG). Blood (ASH Annual Meeting Abstracts), Nov 2008; 112: 917 (Poster presentation).
92. Gutierrez A, Sanda T, Winter SS, Larson RS, Silverman L, Hunger SP, Sallan SE, Look AT. LEF1 is a tumor suppressor in T cell acute lymphoblastic leukemia. Blood (ASH Annual Meeting Abstracts), Nov 2008; 112: 380 (Poster presentation).
93. Harvey RC, Chen I-M, Ar K, Larsen E, Hunger SP, Loh M, Devidas M, Raetz E, Reaman G, Carroll WL, Winick N, Willman CL. Identification of subgroups of high-risk (HR) pediatric precursor B acute lymphoblastic leukemia (B-ALL) by unsupervised microarray analysis: Correlation with clinical variables and merging of data with previous study. A Children's Oncology Group (COG) study. Blood (ASH Annual Meeting Abstracts), Nov 2008; 112: 2256 (Poster presentation).
94. Matloub Y, Bostrom B, Hunger SP, Angiolillo A, Cole C, Thomson B, Devidas M, Heerema N, La M, Buckley P, Carroll W, Winick N, Sather H, Nachman JB, Gaynon PS. Escalating dose intravenous methotrexate without leucovorin rescue during interim maintenance is superior to oral methotrexate for children with standard risk acute lymphoblastic leukemia (SR-ALL): Children’s Oncology Group study 1991. Blood (ASH Annual Meeting Abstracts), Nov 2008; 112: 9 (Oral presentation).
95. Matloub Y, Gaynon PS, Jayabose S, Bostrom B, Hunger SP, Angiolillo A, Devidas M, Linda S, Carroll W, Winick N, Sather H, Pine SR. Bone marrow (BM) minimal residual disease (MRD) at end of induction and interim maintenance is highly predictive of outcome in children with standard risk (SR) acute lymphoblastic leukemia (ALL) treated on the Children’s Oncology Group study 1991. Blood (ASH Annual Meeting Abstracts), Nov 2008; 112: 701 (Oral presentation).
96. Mattano LA, Nachman JB, Devidas M, Winick N, Raetz E, Carroll WL, Whitlock JA, Hunger SP, Larsen EC. Increased incidence of osteonecrosis (ON) with a dexamethasone (DEX) induction for high-risk acute lymphoblastic leukemia (HR-ALL): A report from the Children’s Oncology Group (COG). Blood (ASH Annual Meeting Abstracts), Nov 2008; 112: 898 Poster presentation).
97. Messinger Y, Higgins R, Devidas M, Hunger SP, Carroll A, Heerema N. Acute lymphoblastic leukemia (ALL) with t(8;14)(q11.2;q32): B-lineage disease with high proportion of Down syndrome. A Children’s Oncology Group (COG) study. Blood (ASH Annual Meeting Abstracts), Nov 2008; 112: 147 (Poster presentation).
98. Mullighan CG, Su X, Zhang J, Radtke I, Phillips LA, Miller CB, Ma J, Liu W, Cheng C, Harvey RC, Chen I-M, Clifford R, Carroll WL, Reaman G, Devidas M, Gerhard D, Yang W, Bowman WP, Shurtleff SA, Relling MV, Smith M, Hunger SP, Willman CL, Downing JR. Deletion of IKZF1 (Ikaros) predicts poor outcome and impaired maturation in B-progenitor acute lymphoblastic leukemia. Blood (ASH Annual Meeting Abstracts), Nov 2008; 112: 427 (Oral presentation).
99. Robinson BW, Cao K, Hilden JM, Dinndorf PA, Heerema NA, Sather HN, McGlennen R, Hunger SP, Reaman GH, Wang L-S, Felix CA. Age Is the strongest determinant of leukemia blast cell gene expression in MLL-rearranged infant ALL and MLL-AF4 directs a distinct gene expression profile related to CNS disease. Blood (ASH Annual Meeting Abstracts), Nov 2008; 112: 1200 (Poster presentation).
100. Schultz KR, Bowman P, Slayton WB, Aledo A, Devidas M, Sather H, Borowitz M, Davies S, Trigg M, Pasut B, Jorstad D, Eslinger T, Burden L, Wang CG, Rutledge R, Camitta B, Gaynon P, Carroll A, Heerema NA, Winick N, Hunger SP, Carroll WL. Philadelphia chromosome negative (Ph-) very high-risk (VHR) acute lymphoblastic leukemia (ALL) in children and adolescents: The impact of intensified chemotherapy on early event free survival (EFS) in Children's Oncology Group (COG) study AALL0031. Blood (ASH Annual Meeting Abstracts), Nov 2008; 112: 911 (Poster presentation).
101. Willman CL, Kang H, Harvey RC, Chen I-M, Mullighan C, Downing JR, Relling MV, Zhang J, Gerhard D, Smith M, Dobbin KK, Reaman G, Hunger S. Use of genomic technologies to identify novel genetic abnormalities and therapeutic targets In acute lymphoblastic leukemia. Blood (ASH Annual Meeting Abstracts), Nov 2008; 112: sci-8 (Invited Scientific Abstracts and Mary Rodes Gibson Memorial Award).
102. Wilson BS, Meng X, Mazel T, Willman CL, Atlas S, Harvey R, Chen I-M, Hunger SP, Oliver JM, Winter SS. Select g-secretase inhibitors induce apoptosis in pre-B ALL cells and disrupt the balance between constitutive Notch signaling and repression. Blood (ASH Annual Meeting Abstracts), Nov 2008; 112: 1917 (Poster presentation).
103. Yang J, Yang W, Cheng C, Devidas M, Cao X, Campana D, Borowitz MJ, Willman C, Bowman WP, Reaman GH, Carroll WL, Hunger SP, Evans WE, Pui C-H, Relling MV. Genetically defined racial differences underlie risk of relapse in childhood acute lymphoblastic leukemia. Blood (ASH Annual Meeting Abstracts), Nov 2008; 112: 14 (Oral presentation).
104. Zhang AY, Robinson BW, Cao K, Behling KC, Devidas M, Alonzo TA, Raimondi SC, Carroll AJ, Arceci RJ, Gamis A, Hunger SP, Reaman GH, Harvey R, Willman CL, Wang L-S, Felix CA. Cell death regulatory gene expression correlates with MLL rearrangement status and prognostic clinical covariates in acute leukemia in infants. Blood (ASH Annual Meeting Abstracts), Nov 2008; 112: 2255 (Poster presentation).
105. Zhang AY, Robinson BW, Wang L-S, Cao K, Cory L, Barrett JS, Atlas SB, Willman CL, Devidas M, Carroll AJ, Hunger SP, Moore JS, Thompson CB, Kundu M, Felix CA. Pan-anti-apoptotic BCL-2 family inhibitor, obatoclax, activates autophagic cell death pathway and has potent cytotoxicity in infant and pediatric MLL rearranged leukemias. Blood (ASH Annual Meeting Abstracts), Nov 2008; 112: 2647 (Poster presentation).
106. Nieves R, Reyes D, Moya K, De la Rosa J, Pasut B, Hunger SP. Decreased early mortality with a 3-drug induction regimen for acute lymphoblastic leukemia (ALL) in the Dominican Republic. Poster presentation at the Pediatric Oncology Group of Ontario Multi-disciplinary Symposium 2008.
107. Kelly SS, Kelly P, Hunger SP, Wingard J. Tacrolimus and “mini” methotrexate (MTX) is an effective regimen for prevention of graft-versus-host disease in children undergoing umbilical cord blood transplant. Biol. Blood and Marrow Transplant 15 (Number 2, Supplement 2): 81, 2009 (Poster presentation)
108. Yang JJ, Yang W, Cheng C, Devidas M, Cao X, Campana D, Borowitz MJ, Willman CL, Bowman WP, Reaman GH, Carroll WL, Hunger SP, Evans WE, Pui C-H, Relling MV. Characterization of germline genetic variations underlying racial disparities in childhood leukemia outcome. 2nd AACR Cancer Health Disparities Meeting in February 2009.
109. Leclerc GJ, Sanderson C, Hunger S, Devidas M, Barredo JC. Non-random translocations alter FPGS and other folate-related genes mRNA expression: TEL-AML1 and E2A-PBX1 fusions specifically down-regulate FPGS transcription in cell lines and primary samples of acute lymphoblastic leukemia. Proc AACR, abstract #5687, 2009 (Oral presentation).
110. Mullighan* CG, Zhang* J, Harvey* RC, Collins-Underwood JR, Tasian SK, Schulman BA, Phillips LA, Loh M, Su X, Liu W, Devidas M, Atlas SR, Chen I-M, Clifford RJ, Gerhard D, Carroll WL, Reaman GH, Smith M, Downing# JR, Hunger# SP, Willman# CL. Frequent JAK mutations in pediatric acute lymphoblastic leukemia (ALL) with poor outcome: A new therapeutic target in resistant disease. *CGM, JZ and RCH contributed equally; #JRD, SPH and CLW contributed equally. AACR 2009. Selected for Oral Presentation in the special Spotlight on Breakthroughs in Cancer Research, abstract LB-92, 2009.
111. Schafer ES, Murphy KM, Burns K, McIntyre E, Borowitz MJ, Hunger SP, Wood B, Carroll A, Heerema N, Harvey R, Willman CL, Dreyer Z, Devidas M, Brown P. A custom quantitative real time PCR minimal residual disease (MRD) assay predicts outcome in MLL-rearranged (MLL-R) infant ALL: A Children's Oncology Group study. Pediatr Blood Cancer 52: 694, #P302B, 2009 (Oral Presentation).
112. Hunger SP. Genomic approaches to molecular target identification and validation: Experience in childhood ALL. SIOP 2009; Sao Paolo, Brazil. Pediatr Blood Cancer 53: 707, #S.024, 2009 (Oral Presentation).
113. Hunger S, Mullighan C, Downing J, Relling
M, Willman C, Devidas M, Reaman G, Carroll W, Smith M, Zhang J, Gerhard D. The spectrum of mutations in childhood ALL. SIOP 2009 Award Session; Sao Paolo, Brazil. Pediatr Blood Cancer 53: 730, #O.065, 2009 (Oral Presentation). Winner of SIOP Award for Basic Science
114. Araten DJ, Sanders K, Anscher D, Zamechek L, Hunger SP, Ibrahim S. A high frequency of blasts with the PNH phenotype in patients with ALL. Blood (ASH Annual Meeting Abstracts), Nov 2009; 114: 1575 (Poster presentation).
115. Brown P, Hilden J, Dreyer Z, Winick N, Salzer W, Raetz E, Sung L, Zaoutis T, Jones T, Devidas M, de Lorenzo P, Valsecchi MG, Pieters R, Carroll WL, Hunger SP. Report on excessive induction toxicity in infants with ALL enrolled on COG protocol AALL0631: A Children’s Oncology Group study. Blood (ASH Annual Meeting Abstracts), Nov 2009; 114: 3091 (Poster presentation).
116. Carroll AJ, Heerema NA, Devidas M, Bowman WP, Wang C, Trigg M, Camitta B, Gaynon PS, Winick N, Hunger SP, Carroll WL, Schultz KR. Secondary chromosomal abnormalities appear to be less prognostic for children with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL) treated with intensified imatinib and chemotherapy: Results of the Children’s Oncology Group (COG) study AALL0031. Blood (ASH Annual Meeting Abstracts), Nov 2009; 114: 2606 (Poster presentation).
117. Carroll AJ, Heerema NA, Gastier-Foster JM, Astbury C, Pyatt R, Reshmi SC, Borowitz MJ, Devidas M, Linda S, Loh ML, Raetz EA, Wood B, Winick NJ, Hunger SP, Carroll WL. Masked hypodiploidy: hypodiploid acute lymphoblastic leukemia (ALL) in children mimicking hyperdiploid ALL: A report from the Children’s Oncology Group (COG) AALL03B1 study. Blood (ASH Annual Meeting Abstracts), Nov 2009; 114: 1580 (Poster presentation).
118. Chang BH, Willis SG, Stork L, Hunger SP, Carroll WL, Camitta BM, Winick NJ, Druker BJ, Schultz KR. Mutational analysis of BCR-Abl from subjects with relapsed Ph+ALL treated on the COG protocol AALL0031: a report from the Children’s Oncology Group. Blood (ASH Annual Meeting Abstracts), Nov 2009; 114: 2634 (Poster presentation).
119. Gutierrez A, Grebliunaite R, Dahlberg SE, Neuberg DS, Zhang J, Sanda T, Protopopov A, Chin L, Winter SS, Larson RS, Kutok J, Silverman LB, Hunger SP, Sallan SE, Look AT. Absence of T-cell receptor gene rearrangements predicts induction failure in pediatric T-Cell acute lymphoblastic leukemia. Blood (ASH Annual Meeting Abstracts), Nov 2009; 114: 910 (Oral presentation).
120. Heerema NA, Carroll AJ, Borowitz MJ, Devidas M, Larsen EC, Loh ML, Mattano LA, Maloney KW, Raetz ER, Wood B, Winick NJ, Hunger SP, Carroll WL. Amplification of AML1 does not impact early outcome of children with acute lymphoblastic leukemia (ALL) treated with risk-directed chemotherapy: A report from the Children’s Oncology Group (COG). Blood (ASH Annual Meeting Abstracts), Nov 2009; 114: 2598 (Poster presentation).
121. Hogan L, Bhojwani D, Wang J, Morrison D, Yang JJ, Zhang Y, Zavadil J, Condos G, Hunger SP, Willman CL, Relling MV, Raetz E, Carroll WL. Up-regulation of genes involved in folate metabolism characterize late but not early relapse in childhood acute lymphoblastic leukemia. Blood (ASH Annual Meeting Abstracts), Nov 2009; 114: 1733 (Poster presentation).
122. Matloub Y, Bostrom BC, Angiolillo AL, Devidas M, Heerema NA, Gastier-Foster JM, Hunger SP, Sather H, Linda S, Carroll WL, Nachman JB, Gaynon PS. Children with NCI standard risk acute lymphoblastic leukemia (ALL) and TEL-AML1 or favorable chromosome trisomies are almost certain to be cured with graduated intensity therapy: Results of the CCG-1991 study. Blood (ASH Annual Meeting Abstracts), Nov 2009; 114: 320 (Oral presentation).
123. Mullighan CG, Collins-Underwood JR, Phillips L, Loudin M, Liu W, Zhang J, Ma J, Coustan-Smith E, Harvey R, Willman CL, Cheng J, Mikhail F, Meyer J, Williams RT Carroll AJ, Heerema NA, Basso G, Pession A, Pui C-H, Raimondi SC, Hunger SP, Downing JR, Carroll WL, Rabin KR. Rearrangement of CRLF2 in B-progenitor and Down syndrome associated acute lymphoblastic leukemia. Blood (ASH Annual Meeting Abstracts), Nov 2009; 114: 182 (Oral presentation).
124. Mullighan CG, Morin RD, Zhang J, Hirst M, Zhao Y, Yan C, Finney R, Edmonson M, Su X, Buetow K, Carroll WL, Chen I-M, Devidas M, Gerhard DS, Harvey RC, Hu Y, Loh ML, Reaman GH, Relling MV, Smith M, Downing JR, Hunger SP, Willman CL, Marra M. Next generation transcriptomic resequencing identifies novel genetic alterations in high-risk (HR) childhood acute lymphoblastic leukemia (ALL): A Report from the Children’s Oncology Group (COG) HR ALL TARGET Project. Blood (ASH Annual Meeting Abstracts), Nov 2009; 114: 704 (Oral presentation).
125. Rabin KR, Wang J, Meyer J, Loudin MG, Bhojwani D, Morrison D, Devidas M, Heerema NA, Carroll AJ, Pession A, Basso G, Mullighan CG, Hunger SP, Carroll WL. Gene expression profiling in Down syndrome acute lymphoblastic leukemia identifies distinct profiles associated with CRLF2 expression status. Blood (ASH Annual Meeting Abstracts), Nov 2009; 114: 2389 (Poster presentation).
126. Robinson BW, Devidas M, Carroll AJ, Harvey RC, Heerema NA, Willman CL, Hudome A, Woods EC, Ballantyne N, Reaman GH, Hilden JM, Camitta BM, Winick NJ, Carroll WL, Hunger SP, Dreyer ZE, Felix CA. Specific MLL partner genes in infant acute lymphoblastic leukemia (ALL) associated with outcome are linked to age and white blood cell count (WBC) at diagnosis: A Report on the Children’s Oncology Group (COG) P9407 Trial. Blood (ASH Annual Meeting Abstracts), Nov 2009; 114: 907 (Oral presentation).
127. Wood B, Winter SS, Dunsmore K, Raetz EA, Borowitz MJ, Devidas M, Winick NJ, Carroll WL, Hunger SP, Loh ML. Patients with early T-cell precursor (ETP) acute lymphoblastic leukemia (ALL) have high levels of minimal residual disease (MRD) at the end of induction—A Children’s Oncology Group (COG) Study. Blood (ASH Annual Meeting Abstracts), Nov 2009; 114: 9 (Oral presentation).
128. Zhang J, Mullighan CG, Harvey RC, Buetow KE, Carroll WL, Chen I-M, Devidas M, Edmonson M, Gerhard DS, Hu Y, Loh ML, Phillips LA, Reaman GH, Relling MV, Smith M, Downing JR, Willman CL, Hunger SP. Mutations in the RAS signaling, B-cell development, TP53/RB1, and JAK signaling pathways are common in high risk B-precursor childhood acute lymphoblastic leukemia (ALL): A Report from The Children’s Oncology Group (COG) High-risk (HR) ALL TARGET Project. Blood (ASH Annual Meeting Abstracts), Nov 2009; 114: 85 (Oral presentation).
129. Gutierrez A, Dahlberg SE, Neuberg DS, Zhang J, Grebliunaite R, Sanda T, Protopopov A, Kutok J, Winter SS, Larson RS, Borowitz MJ, Loh M, Silverman LB, Hunger SP, Sallan SE, Look AT. Absence of Biallelic TCRγ Deletions (ABGD) Predicts Induction Failure in Pediatric T-ALL. Pediatr Blood Cancer 54: 812, #167, 2010 (Poster Presentation).
130. Heerema NA, Raetz EA, Carroll AJ, Borowitz MJ, Devidas M, Larsen EC, Loh ML, Mattano LA, Maloney KW, Wood B, Winick NJ, Hunger SP, Carroll WL. Amplification of AML1 does not impact early event-free survival (EFS) or overall survival (OS) of children with acute lymphoblastic leukemia (ALL) treated with risk-directed chemotherapy: A report from the Children’s Oncology Group (COG). Pediatr Blood Cancer 54: 816, #181, 2010 (Poster Presentation).
131. Hogan LE, Meyer JA, Wang J, Morrison D, Yang JJ, Hunger S, Willman CL, Relling MV, Raetz EA, Bhojwani D, Carroll WL. Gene Expression Analysis Reveals Distinct Signatures for Early and Late Relapse in Pediatric Acute Lymphoblastic Leukemia (ALL). Pediatr Blood Cancer 54: 790, #303B, 2010 (Platform Session).
132. Loh ML Winter SS, Dunsmore K, Raetz EA, Borowitz MJ, Devidas M, Winick NJ, Carroll WL, Hunger SP, Wood B. Patients with early T-cell precursor (ETP) acute lymphoblastic leukemia (ALL) have high levels of minimal residual disease (MRD) at the end of induction—A Children’s Oncology Group (COG) Study. Pediatr Blood Cancer 54: 788, #301A, 2010 (Platform Session).
133. Schultz KR, Bowman WP, Aledo A, Slayton WB, Sather H, Devidas M, Wang C, Davies SM, Gaynon PS, Trigg M, Rutledge R, Burden L, Jorstad D, Carroll A, Heerema N, Winick N, Borowitz MJ, Hunger SP, Carroll WL, Camitta B. Continuous Dosing Imatinib with Intensive Chemotherapy gives Equivalent Outcomes To Allogeneic BMT for Philadelphia Chromosome-positive (Ph+) Acute Lymphoblastic Leukemia (ALL) with Longer Term Follow Up: Updated Results of Children’s Oncology Group (COG) AALL0031. Pediatr Blood Cancer 54: 788, #300B, 2010 (Plenary Platform Session).
134. Hogan LE, Mason C, Meyer J, Wang J, Tang Z, Brown S, Morrison DJ, Hunger S, Raetz EA, Carroll WL. High throughput transcriptome sequencing of pediatric relapsed acute lymphoblastic leukemia (ALL). J Clin Oncol 28: 7s, 2010 (suppl; abstr 9521; ASCO 2010 poster discussion session).
135. Daves MH, Hunger S, Linda SB, Bowman WP, Seibel NL, Sung L, Devidas M. Longer Time to the Start of Continuation Therapy Is Associated with Improved Survival In High Risk Pediatric Acute Lymphoblastic Leukemia (ALL): A Report From the Children’s Oncology Group (COG). Blood (ASH Annual Meeting Abstracts), Nov 2010; 116: 3223a (Poster presentation).
136. Downie J, Barnette P, Rodic V, Frazer JK, Trede N, Devidas M, Mullighan C, Hunger S, Miles RR, Schiffman JD. T-Cell Receptor Gene Deletions Are Associated with High Risk Features and Worse Outcome In Childhood Precursor B-Cell Acute Lymphoblastic Leukemia (ALL). Blood (ASH Annual Meeting Abstracts), Nov 2010; 116: 275a (Oral presentation).
137. Gutierrez A, Kentsis A, Sanda T, Etchin J, Protopopov A, Zhang J, Chin L, Silverman L, Winter S, Hunger S, Sallan S, Zha S, Alt F, Look AT. BCL11B is a Tumor Suppressor Mutated in T-Cell Acute Lymphoblastic Leukemia. Blood (ASH Annual Meeting Abstracts), Nov 2010; 116: 4177a (Poster presentation).
138. Holmfeldt L, Zhang J, Ma J, Devidas M, Carroll AJ, Heerema NA, Gastier-Foster JM, Raimondi SC, Loh ML, Hunger SP, Mullighan C. Genome-Wide Analysis of Genetic Alterations In Hypodiploid Acute Lymphoblastic Leukemia Identifies a High Frequency of Mutations Targeting the IKAROS Gene Family and Ras Signaling. Blood (ASH Annual Meeting Abstracts), Nov 2010; 116: 411a (Oral presentation).
139. Kang H, Wilson CS, Harvey RC, Chen I-M, Murphy MH, Atlas SR, Bedrick EJ, Devidas M, Carroll AJ, Robinson BW, Heerema NA, Hilden JM, Dreyer ZE, Camitta B, Winick N, Carroll WL, Felix CA, Reaman GH, Hunger SP, Willman CL. Gene Expression Profiling Reveals Genes Predictive of Outcome In Infant Acute Lymphoblastic Leukemia (ALL) and Distinctive Age-Related Gene Expression Profiles (< 90 Days vs. > 90 Days): A Children’s Oncology Group Study. Blood (ASH Annual Meeting Abstracts), Nov 2010; 116: 412a (Oral presentation).
140. Maloney KW, Loh M, Raetz E, Borowitz MJ, Devidas M, Friedmann A, Mattano LA, Wood B, Winick N, Hunger SP, Carroll WL. Early response characteristics and blast cytogenetic features in 5,377 children with standard risk acute lymphoblastic leukemia (SR-ALL): A Children’s Oncology Group (COG) study. Blood (ASH Annual Meeting Abstracts), Nov 2010; 116: 414a (Oral presentation).
141. Matloub Y, Bostrom BC, Hunger SP, Angiolillo AL, Devidas M, La M, Heerema N, Nachman N, Sather H, Carroll WL, Gaynon PS. Children with Down Syndrome (DS) and NCI Standard Risk (SR) Acute Lymphoblastic Leukemia (ALL) Have a Superior Five-Year Event-Free Survival (EFS) When Treated With Escalating Intravenous Methotrexate on the Children’s Cancer Group (CCG) Study 1991. Blood (ASH Annual Meeting Abstracts), Nov 2010; 116: 497a (Oral presentation).
142. Meyer JA, Hogan LE, Wang J, Yang JJ, Patel J, Levine RL, Hunger SP, Raetz E, Mason C, Carroll WL. High Throughput Transcriptome Sequencing of Pediatric Relapsed Acute Lymphoblastic Leukemia (ALL) Identifies Relapse Specific Mutations and Expression. Blood (ASH Annual Meeting Abstracts), Nov 2010; 116: 3233a (Poster presentation).
143. Salzer WL, Asselin B, Supko JG, Devidas M, Kaiser NA, Plourd P, Winick NJ, Reaman GH, Raetz E, Carroll WL, Hunger SP. Administration of Erwinia Asparaginase (Erwinase®) Following Allergy to PEG-Asparaginase in Children and Young Adults with Acute Lymphoblastic Leukemia Treated on AALL07P2 Achieves Therapeutic Nadir Serum Asparaginase Activity: A Report from the Children’s Oncology Group (COG). Blood (ASH Annual Meeting Abstracts), Nov 2010; 116: 2134a (Poster presentation).
144. Slovak ML, Ning Y, Yu L, Hunger S, Carroll AJ, Brown TC, Campbell LJ, Wall M, Crawford E, Fang M, Kolquist K, Saleki R, Shaffer LG, Ballif B, Schultz R. Targeted Microarray Analyses Augment the Clinical Cytogenetic Diagnosis of Acute Lymphoblastic Leukemia (ALL): Submicroscopic Genetic Events Improve Diagnosis, Contribute to Risk Stratification, and Provide Genetic Markers for Minimal Residual Disease (MRD) Testing. Blood (ASH Annual Meeting Abstracts), Nov 2010; 116: 2690a (Poster presentation).
145. Tasian SK, Doral MY, Wood BL, Collins-Underwood JR, Borowitz MJ, Harvey RC, Sakamoto KM, Willman CL, Hunger SP, Mullighan CG, Loh ML. Thymic Stromal Lymphopoietin Stimulation of Pediatric Acute Lymphoblastic Leukemias with CRLF2 Alterations Induces JAK/STAT and PI3K Phosphosignaling. Blood (ASH Annual Meeting Abstracts), Nov 2010; 116: 410a (Oral presentation).
146. Teachey DT, Vincent T, Willman CL, Loh ML, Mullighan C, Hunger S, Grupp SA. Targeting mTOR signaling is an effective treatment strategy for IKAROS and JAK kinase mutated acute lymphoblastic leukemia. Blood (ASH Annual Meeting Abstracts), Nov 2010; 116: 3251a (Poster presentation).
147. Urtishak KA, Wang L-S, Harvey R-C, Atlas S, Chen I-M, Robinson BW, Moukarzel L, Cao K, Devidas M, Carroll AJ, Heerema NA, Hunger SP, Reaman GH, Hilden JM, Camitta BM, Winick NJ, Carroll WL, Zhang AY, Cory L, McVeigh S, Barrett JS, Dreyer ZE, Willman SL, Felix CA. Infant Acute Lymphoblastic Leukemias (ALL) Are Pan-Sensitive to Obatoclax Across Molecular/Cytogenetic Subtypes, Especially MLL-ENL, and Gene Expression Profiles Determine Obatoclax IC50: A Report on the Children’s Oncology Group (COG) P9407 Trial. Blood (ASH Annual Meeting Abstracts), Nov 2010; 116: 2757a (Poster presentation).
148. Winter SS, Devidas M, Wood B, Borowitz MJ, Loh ML, Asselin B, Murphy B, Raetz E, Winick N, Hunger S, Carroll W, Dunsmore K. Nelarabine May Be Safely Incorporated Into a Phase III Study for Newly Diagnosed T-Lineage Acute Lymphoblastic Leukemia: A Report From the Children’s Oncology Group. Blood (ASH Annual Meeting Abstracts), Nov 2010; 116: 865a (Oral presentation).
149. Yang JJ, Xu H, Cheng C, Devidas M, Pei D, Fan Y, Yang W, Neale G, Winick NJ, Martin PL, Willman CL, Camitta BM, Reaman GH, Carroll WL, Loh M, Hunger SP, Evans WE, Relling MV. ARID5B Genetic Polymorphisms Contribute to Racial Disparities in Childhood Acute Lymphoblastic Leukemia: A Children’s Oncology Group Study. Blood (ASH Annual Meeting Abstracts), Nov 2010; 116: 8a (Oral presentation).
150. Zhang J, Mullighan CG, Harvey RC, Carroll WL, Chen I-M, Devidas M, Larsen E, Edmonson M, Buetow K, Gerhard DS, Loh ML, Reaman GH, Relling MV, Smith MA, Downing JR, Willman CL, Hunger SP. Lack of somatic sequence mutations in protein tyrosine kinase genes other than the JAK kinase family in high risk B-precursor childhood acute lymphoblastic leukemia (ALL): A report from The Children’s Oncology Group (COG) High-Risk (HR) ALL TARGET Project. Blood (ASH Annual Meeting Abstracts), Nov 2010; 116: 2752a (Poster presentation).
151. Holmfeldt L, Zhang J, Payne-Turner D, Ma J, Devidas M, Carroll AJ, Heerema NA, Gastier-Foster JM, Raimondi SC, Loh ML, Hunger SP, Mullighan C. Genome wide analysis of hypodiploid acute lymphoblastic leukemia identifies a high frequency of mutations targeting the IKAROS gene family and Ras signaling. Accepted for Oral Presentation at AACR 2011.
152. Brown P, Kaeding AJ, Magoon D, Small D, Jones T, Devidas M, Carroll AJ, Heerema NA, Loh M, Raetz E, Winick N, Carroll WL, Hilden JM. Hunger S. Identification of a safe and biologically active dose of the FLT3 inhibitor lestaurtinib in combination with chemotherapy in infants with MLL-rearranged (MLL-4) ALL: A Children’s Oncology Group Study. Submitted for ASPHO 2011. Accepted for Oral Presentation at ASPHO 2011. Pediatr Blood Cancer 56: 899, #302B, 2011 (Platform Session oral presentation).
153. Lew G, Yanofsky R, Winick N, Rheingold S, Jorstad D, Lu X, Devidas M, Whitlock J, Hunger S, Carroll W. Intensive vincristine is not feasible in intermediate-risk relapse of childhood acute lymphoblastic leukemia (ALL): A report from Children’s Oncology Group study AALL0433. Pediatr Blood Cancer 56: 919, 2011 (poster presentation).
154. Maloney K, Larsen E, Mattano L, Friedmann A, Devidas M, Nachman J, Raetz E, Winick N, Whitlock J, Hunger SP, Carroll WL. Improved toxic mortality rates for children with Down syndrome acute lymphoblastic leukemia (DS-ALL) treated on Children’s Oncology Group (COG) trials for standard risk (SR; AALL0331) but not high risk (HR; AALL0232) ALL. Pediatr Blood Cancer 56: 900, #303B, 2011 (Platform Session oral presentation).
155. Salzer WL, Asselin B, Supko JG, Devidas M, Kaiser NA, Plourd PV, Winick NJ, Reaman GH, Raetz E, Carroll WL, Hunger SP. Administration of Erwinia Asparaginase Following Allergy to PEG-Asparaginase in Children and Young Adults with Acute Lymphoblastic Leukemia Achieves Therapeutic Nadir Serum Asparaginase Activity: A Report from the Children’s Oncology Group (COG). Pediatr Blood Cancer 56: 922, 2011 (poster presentation).
156. Chen IM, Harvey R, Mullighan CG, Loh ML, Devidas M, Borowitz MJ, Tasian SK, Payne-Turner D, Wharton W, Pullen J, Carroll AJ, Carroll WL, Camitta BM, Hunger S, Winick NJ, Willman CL. High CRLF2 expression predicts poor outcome in high-risk, but not standard-risk, pediatric b-cell precursor acute lymphoblastic leukemia (BCP-ALL). A report from the Children’s Oncology Group. J Clin Oncol 29: 586s, 2011 (suppl; abstr 9505; ASCO 2011 Oral Session presentation).
157. Larsen EC, Salzer WL, Devidas M, Nachman JB, Raetz EA, Loh ML, Heerema NA, Carroll AJ, Gastier-Foster JM, Borowitz MJ, Wood BL, Willman CL, Winick NJ, Hunger S, Carroll W. High dose methotrexate (HD-MTX) as compared to capizzi methotrexate plus asparaginase (C-MTX/ASNase) improves event-free survival (EFS) in children and young adults with high-risk acute lymphoblastic leukemia (HR-ALL): A report from the Children’s Oncology Group study AALL0232. J Clin Oncol 29: 6s, 2011 (suppl; abstr 3; ASCO 2011 Plenary Session presentation).
158. Winick NJ, Salzer WL, Devidas M, Nachman JB, Raetz EA, Loh ML, Heerema NA, Carroll AJ Gastier-Foster JM, Borowitz MJ, Wood BL, Willman CL, Hunger S, Carroll WL, Larsen EC. Dexamethasone (DEX) versus prednisone (PRED) during induction for children with high risk acute lymphoblastic leukemia (HR-ALL): a report from the Children’s Oncology Group study AALL0232. J Clin Oncol 29: 586s, 2011 (suppl; abstr 9504; ASCO 2011 Oral Session presentation).
159. Vattathil S, San Lucas FA, Fan Y, Yang W, Wang W, Hunger SP, Loh M, Devidas M, Pui C-H, Mardis E, Relling MV, Scheet P. An evaluation of the informativeness of population genetics when making genotype calls in exome-captured next generation sequencing data. Submitted for American Journal of Human Genetics meeting 2011.
160. Hunger SP, Reyes D, Negrin O, Montero M, De la Rosa I, Moya K, Pasut B, Lauzardo M, Nieves R. Decreased early mortality and increased survival with less intensive therapy for acute lymphoblastic leukemia (ALL) in the Dominican Republic. Accepted for Poster Presentation at SIOP 2011.
161. Barredo JC, Hastings C, Lu X, Marcus R, Winick N, Devidas M, Whitlock J, Ritchey AK, Hunger S, William Carroll. Inferior outcome with reduced dose cranial radiation (12 Gy) in isolated CNS relapse of ALL treated with intensive systemic chemotherapy: A Children’s Oncology Group study. Accepted for Oral Presentation at SIOP 2011.
Invited Presentations
1. American Society of Hematology Annual Meeting Simultaneous Session, Anaheim, CA; December 7th, 1992; The t(17;19) derived chimeric protein E2A-HLF displays dominant negative transcriptional regulatory properties
2. American Society of Clinical Oncology Annual Meeting Simultaneous Session, Orlando, FL; May 17th, 1993; Long-term results of ABVD/MOPP and low dose involved field radiotherapy in pediatric Hodgkin’s disease: The Stanford experience
3. American Society of Hematology Annual Meeting Simultaneous Session, St. Louis, MO; December 6th, 1993; The DNA binding and transcriptional regulatory properties of E2A-HLF diverge from those of wild type HLF
4. American Society of Hematology Annual Meeting Simultaneous Session, Seattle, WA; December 4th, 1995; Delineation of a highly conserved transcriptional activation domain in HLF and TEF
5. Society for Hematopathology Scientific Symposium--Molecular Pathology of Hematopoietic Neoplasms: Pathogenetic Insights and Diagnostic Applications; Toronto, Canada; March 12th, 1996; Mechanisms of Transformation in Acute Lymphoblastic Leukemia
6. Seminar on Flow Cytometry and Related Parameters; V.A. Medical Center, Denver, CO; September 13th, 1996; Molecular Pathogenesis of Leukemias and Lymphomas
7. Children’s Cancer Group Spring Meeting; Atlanta, GA; April 11th, 1997; Molecular genetic studies of pediatric ALL
8. Children’s Cancer Group Retreat on Relapsed ALL; Snowbird, UT; September 13, 1997; Genetic analysis of relapsed ALL
9. American Society of Hematology Annual Meeting Simultaneous Session, San Diego, CA; December 8th, 1997; E2A-PBX1 chimeric transcript status at end of consolidation is not predictive of treatment outcome in childhood acute lymphoblastic leukemias with a t(1;19)(q23;p13): A Pediatric Oncology Group study
10. American Society of Hematology Annual Meeting, San Diego, CA; December 8th, 1997; Co-Chair for Simultaneous Session Prognostic Factors of Acute Leukemia
11. International Bone Marrow Transplant Registry/Autologous Bone Marrow Transplant Registry, Keystone, CO; January 11th, 1998; Value of monitoring minimal residual disease in the management of acute lymphoblastic leukemia
12. Oncology Grand Rounds, St. Jude Children’s Research Hospital, Memphis, TN; January 29th, 1998; Just Because It’s Intuitively Obvious Doesn’t Mean It’s Correct: Detection of Mininimal Residual Disease in t(1;19)+ ALL
13. Children’s Cancer Group Spring Meeting; Houston, TX; April 23rd, 1998; The role of p16INK4A/p15INK4B deletions in the progression of childhood ALL
14. Seminar on Molecular Genetics in Hematologic Neoplasms; V.A. Medical Center, Denver, CO; September 25th, 1998; Cooperative Mutations in Lymphoid Malignancies
15. Grand Rounds; The Children’s Hospital, Denver CO; December 10, 1999; Treatment of Childhood Acute Lymphoblastic Leukemia: Current Status and Challenges for the New Millenium
16. Children’s Oncology Group Spring Meeting; Tampa, FL; April 12th, 2000; Detection of E2A translocations by fluoresence in situ hybridization
17. Leukemia and Lymphoma Society Translational Grant Awardees Meeting; Washington, D.C.; September 13th, 2000; Molecular Genetics of Relapsed Childhood ALL
18. Children’s Oncology Group Fall Meeting; Phoenix, AZ; November 1, 2000; Molecular Heterogeneity in Pediatric Leukemias with a t(10;11)
19. American Society of Hematology Annual Meeting Simultaneous Session, San Francisco, CA; December 4th, 2000; FISH detection of E2A translocations in leukemia
20. American Society of Hematology Annual Meeting, San Francisco, CA; December 4th, 2000; Co-Chair for Simultaneous Session The Impact of Biology and Genetics on Outcome
21. Grand Rounds; Department of Pediatrics, University of Florida, Gainesville, FL; January 26, 2001; Treatment of Childhood Acute Lymphoblastic Leukemia: Current Status and Challenges for the New Millenium
22. American Society of Pediatric Hematology/Oncology Annual Meeting, Baltimore, MD; April 26th, 2001; Young Investigator Workshop (Organizer and Chair); Career Development Pathways for the Young Investigator
23. University of Florida Chapter of Friends for Life; September 20th, 2001; New Developments in the Treatment of Leukemia
24. University of Florida Shands Cancer Center “Topics in Cancer and Cell Biology” Seminar; September 21st, 2001; Chromosome Translocations in Lymphoid Malignancies: Identification of New Oncogenes from 19p13
25. Families R.O.C.K. Weekend (Reach out to Cancer Kids, sponsored by Florida Division of the American Cancer Society), Orlando, FL; September 29th, 2001; Disease Specific Breakout Moderator: Leukemia
26. University of Florida Hematologic Malignancies Seminar Series; October 5th, 2001; Treatment of Acute Lymphoblastic Leukemia: Lessons from Pediatric Oncology
27. University of Florida Shands Cancer Center Conference “Update in Hamatologic Malignancies and Stem Cell Transplantation”; October 12th, 2001; Treatment of Acute Lymphoblastic Leukemia: Lessons from Pediatric Oncology
28. American Society of Hematology Annual Meeting, Orlando, FL; December 11th, 2001; Co-Chair for Simultaneous Session Acute Lymphoblastic Leukemia-Prognostic Markers
29. Grand Rounds, Wolfson Children’s Hospital, Jacksonville, FL: December 13th, 2001; Acute Lymphoblastic Leukemia in Children and Adolescents: Current Status and Challenges
30. Joint Cancer Conference of the Florida Universities; Orlando, FL: January 31st, 2002; Treatment of ALL in Children and Adolescents: Lessons for Adults
31. Daniel Burton Endowment Fund Lecture in Leukemia, Grand Rounds, The Hospital for Sick Children, Toronto, Ontario, Canada: May 8, 2002: Acute Lymphoblastic Leukemia in Children and Adolescents: Current Status and Challenges
32. STOP! Children’s Cancer Annual Luncheon Keynote Speaker, Palm Beach, FL, May 9th, 2002: Childhood Cancer
33. University of Florida Shands Cancer Center Grand Rounds, September 24th, 2002; Leukemia: Mechanisms, Timing and Target Cells for Transformation
34. University of Florida Shands Cancer Center Conference “Update in Hamatologic Malignancies and Stem Cell Transplantation”; November 9th, 2002; Gleevec and Beyond: The New Era of Molecularly Targeted Therapies
35. Florida Association of Pediatric Tumor Programs 25th Anniversary Advances in Pediatric Hematology/Oncology Seminar; November 15th, 2002; Molecularly Targeted Therapies in Pediatric Cancer
36. American Society of Hematology Annual Meeting, Philadelphia, PA; December 9th, 2002; Co-Chair for Simultaneous Session Disordered Gene Expression in Hematologic Malignancy II
37. Families R.O.C.K. Weekend (Reach out to Cancer Kids, sponsored by Florida Division of the American Cancer Society), Orlando, FL; December 14th, 2002; Keynote Speaker: What’s New in Childhood Cancer: 2002 and Beyond
38. Families R.O.C.K. Weekend (Reach out to Cancer Kids, sponsored by Florida Division of the American Cancer Society), Orlando, FL; December 14th, 2002; Disease Specific Breakout Moderator: Leukemia
39. Grand Rounds, Department of Pediatrics, Shands University Hospital, Jacksonville, FL: January 10th, 2003; Acute Lymphoblastic Leukemia in Children and Adolescents: Current Status and Challenges
40. Ocala Women’s Council of Realtors Annual Fashion Show Keynote Speaker, Ocala, FL, May 2nd, 2003: Childhood Cancer
41. STOP! Children’s Cancer Annual Luncheon Keynote Speaker, Palm Beach, FL, May 9th, 2003: Childhood Cancer
42. Shands Hospital at the University of Florida Bone Marrow Transplant Physician Assistant Teaching Conference; Gainesville, FL; August 18, 2003; Pediatric Leukemia and the Role of Stem Cell Transplantation
43. Families R.O.C.K. Weekend (Reach out to Cancer Kids, sponsored by Florida Division of the American Cancer Society), Orlando, FL; August 30th, 2003; Disease Specific Breakout Moderator: Leukemia
44. Shands Hospital at the University of Florida Bone Marrow Transplant Physician Assistant Teaching Conference; Gainesville, FL; September 15, 2003; Pediatric Solid Tumors and the Role of Stem Cell Transplantation
45. University of Florida Student Health Center Quarterly CME Meeting for Practitioners, Gainesville, FL; September 23, 2003; Cancer in Adolescents and Young Adults
46. University of Florida Shands Cancer Center Grand Rounds, October 28th, 2003; Gleevec: Molecularly Targeted Therapy for CML and How to Outsmart It
47. Florida Association of Pediatric Tumor Programs 26th Anniversary Advances in Pediatric Hematology/Oncology Seminar; Orlando FL; November 13-15th, 2003; Conference Medical Director and Organizer
48. Florida Association of Pediatric Tumor Programs 26th Anniversary Advances in Pediatric Hematology/Oncology Seminar; Orlando FL; November 14h, 2003; Cancer Treatment for the Adolescent and Young Adult
49. Sixth International Childhood Acute Lymphoblastic Leukemia Ponte di Legno Working Group Meeting, Coronado Island CA; December 4th, 2003; Favorable Chromosome Trisomies: The Children’s Oncology Group Experience
50. Grand Rounds, Department of Surgery, University of Florida College of Medicine, Gainesville, FL: January 14th, 2004; Treatment of Neuroblastoma
51. STOP! Children’s Cancer Annual Luncheon Keynote Speaker, Palm Beach, FL, May 7th, 2004: Childhood Cancer
52. University of Minnesota Comprehensive Cancer Center, Minneapolis MN; May 10th, 2004: A Variant t(1;19)(q23;p13) in childhood ALL fuses MEF2D and DAZ-AP1
53. American Society of Clinical Oncology Annual Meeting, New Orleans, LA; June 5th and June 6th, 2004; Clinical Problems in Oncology, Controversies of Stem Cell Transplantation for Pediatric Cancer: The Role of Stem Cell Transplantation in Infant Acute Lymphoblastic Leukemia
54. American Society of Clinical Oncology Annual Meeting, New Orleans, LA; June 6th, 2004; Chair for Oral Presentation Session Pediatric Cancer II
55. Grand Rounds, Department of Pediatrics, University of Florida College of Medicine, Gainesville, FL: September 3rd, 2004; Cancer Treatment for the Adolescent and Young Adult: The Role of Pediatric Physicians
56. University of Florida Chapter of Friends for Life; October 7th, 2004; Pediatric Oncology
57. Florida Association of Pediatric Tumor Programs 27th Anniversary Advances in Pediatric Hematology/Oncology Seminar; November 12th, 2004; The Next Generation of COG ALL Trials
58. American Society of Hematology Annual Meeting, San Diego, CA; December 6th, 2004; Moderator for Simultaneous Session Cytogenetic and Molecular Markers of Prognosis in ALL
59. Brainstorming in Childhood ALL Ponte di Legno Working Group Meeting; Palermo, Italy; January 28th, 2005; Proposed New Definitions of Relapse in Childhood ALL
60. BMT Pharmacists Conference; Tandem BMT Meetings; Keystone, CO; February 10th, 2005: Acute Lymphoblastic Leukemia-Advances? Yes!
61. Eighth Annual International Childhood Acute Lymphoblastic Leukemia Ponte di Legno Working Group Meeting; Vienna, Austria; April 27th 2005; Definition of remission and relapse in ALL: Impact of MRD
62. Sixteenth Annual International BFM Study Group Meeting; Vienna, Austria; April 30th 2005; Plenary Session Presentation and Roundtable Discussion: Definition of remission and relapse in ALL: Are new approaches required?
63. American Society of Clinical Oncology Annual Meeting, Orlando, FL; May 14th, 2005; Educational Session Chair and Speaker: Detection of minimal residual disease in childhood cancers: technology and applications
64. Symposium, Orlando, FL, May 15th, 2005: Treatment of acute lymphoblastic leukemia in children and adolescents: current status and challenges
65. STOP! Children’s Cancer Annual Luncheon Keynote Speaker, Palm Beach, FL, May 20th, 2005: Childhood Cancer
66. American Society of Hematology Clinical Research Training Institute, Dana Point, CA, August 11, 2005: Translational research in Hematology/Oncology
67. International Society of Paediatric Oncology 37th Congress, Vancouver, BC, Canada; September 22, 2005; Educational Session: State of the art treatment of acute lymphoblastic leukemia
68. Japan Pediatric Leukemia Study Group, First Annual Academic Meeting, Tokyo, Japan; October 8, 2005; The role of stem cell transplantation in infant ALL
69. CARES, University of Florida Gainesville FL; November 8th, 2005; Pediatric Cancer and Opportunities to Help
70. Robert Reid Cabral Hospital, Santo Domingo, Dominican Republic; November 15, 2005; Childhood acute lymphoblastic leukemia: Improving outcomes through collaboration
71. 5th Asparaginase Experts Session, Atlanta GA; December 10th, 2005; Intensified PEG Asparaginase Treatment in COG ALL Trials
72. University of Florida Shands Cancer Center Grand Rounds, December 14th, 2005; Asparagine Synthetase and Asparaginase: From Nutritional Biochemistry to Leukemia Biology
73. Seventeenth Annual International BFM Study Group Meeting; Noordwijkerhout, The Netherlands; April 28th 2006; COG acute lymphoblastic leukemia trials 2006: Ongoing studies and new initiatives
74. Seventeenth Annual International BFM Study Group Meeting; Noordwijkerhout, The Netherlands; April 29th 2006; Acute lymphoblastic leukemia gene expression profiles at diagnosis and relapse
75. 5th Bi-annual Symposium on Childhood Leukemia; Noordwijkerhout, The Netherlands; May1st 2006; Acute lymphoblastic leukemia gene expression profiles and treatment response
76. American Society of Hematology Clinical Research Training Institute, Dana Point, CA, August 11, 2006: Translational research in Hematology/Oncology: Developing Effective Research Partnerships
77. Robert Reid Cabral Hospital Fiftieth Anniversary Celebration, Santo Domingo, Dominican Republic; August 26th, 2006; Childhood acute lymphoblastic leukemia: Yesterday, today and tomorrow
78. University of Florida Chapter of Friends for Life; September 28th, 2006; Pediatric Oncology
79. Children’s Oncology Group and United Kingdom Childhood Leukemia Study Group Joint Leadership Meeting; Orlando, FL; December 8, 2006; COG ALL Trials 2006: Major Observations and New Initiatives
80. International Childhood Leukemia Array Consortium Meeting; Orlando FL; December 8, 2006; Development and Testing of Universal Gene Signatures in Childhood ALL: A Proposal for Collaboration
81. The Hospital for Sick Children, Toronto, Ontario, Canada; January 8th, 2007: Childhood Acute Lymphoblastic Leukemia: Key Questions for Future Research
82. Stem Cell Transplantation in Children: Current Results and Controversies—Meeting #9, San Diego, CA; January 16th, 2007: Moderator Session #1: Acute lymphoblastic leukemia: Where does transplant fit it?
83. Stem Cell Transplantation in Children: Current Results and Controversies—Meeting #9, San Diego, CA; January 16th, 2007: The role of stem cell transplant for children with acute lymphoblastic leukemia in first remission
84. Xth Congress of the Association of Central American Pediatric Hematologists and Oncologists (AHOPCA); Juan Dolio, Dominican Republic; February 16th, 2007: Acute Lymphoblastic Leukemia Treatment Regimens for Use in Developing Countries: A Proposal (delivered in absentio by Scott Howard, MD)
85. Pediatric Hematology/Oncology Grand Rounds; Children’s Hospital, University of Texas Southwestern Medical School; Dallas, TX; February 27, 2007: Acute lymphoblastic leukemia panel discussion
86. Hematology/Oncology Grand Rounds, Department of Medicine; University of Florida; Gainesville FL; March 12th, 2007: Treatment of acute lymphoblastic leukemia in adolescents and young adults
87. The Children’s Hospital, Denver, CO; April 2nd, 2007: Childhood Acute Lymphoblastic Leukemia: Key Questions for Future Research
88. Children’s Oncology Group and United Kingdom Childhood Leukemia Study Group Joint Leadership Meeting; Brugge, Belgium; May 4, 2007; COG ALL Trials 2007: Updates and Plans for Future Trials
89. Eighteenth Annual International BFM Study Group Meeting; Brugge, Belgium; May 4, 2007; COG acute lymphoblastic leukemia trials 2007: Major Observations and new initiatives
90. Eighteenth Annual International BFM Study Group Meeting; Brugge, Belgium; May 4, 2007; COG acute lymphoblastic leukemia trials 2007: Novel agent and relapse trials
91. American Society of Hematology Clinical Research Training Institute, Dana Point, CA, August 9, 2007: Conducting Clinical Research Within Cooperative Groups
92. American Society of Hematology Clinical Research Training Institute, Dana Point, CA, August 10, 2007: Evidence-Based Health Care
93. Ninth Annual International Childhood Acute Lymphoblastic Leukemia Ponte di Legno Working Group Meeting; Atlanta, GA; December 6th 2007; Outcome of patients with ALL and a t(17;19)
94. International Childhood ALL New Agents Meeting; Nashville, TN; February 2nd 2008; Definitions of relapse and response for relapsed ALL
95. Second St. Jude-VIVA Forum on Hematological Malignancies in Children; Singapore; March 5, 2008; Meet the Expert Lunch Session: Treatment of childhood acute lymphoblastic leukemia
96. Second St. Jude-VIVA Forum on Hematological Malignancies in Children; Singapore; March 6, 2008; Acute lymphoblastic leukemia trials in the Children’s Oncology Group
97. St. Luke’s International Hospital; Tokyo, Japan; April 18, 2008; The Children's Oncology Group ALL Committee: Progress Following Merger, Updates and Plans for Future Trials
98. 11th Annual Infant Leukemia Conference; Tokyo, Japan; April 19, 2008; Infant acute lymphoblastic leukemia: The Children's Oncology Group experience
99. Hiroshima University School of Medicine; Hiroshima, Japan; April 22, 2008; The Children's Oncology Group ALL Committee: Progress Following Merger, Updates and Plans for Future Trials
100. Matsuyama University School of Medicine; Matsuyama, Japan; April 23, 2008; Children's Oncology Group Trials for Children, Adolescents and Young Adults
101. Institute of Childhood Health/Great Ormond Street Hospital Childhood Leukaemia Symposium on the Molecular Basis of Childhood Leukaemia; London, Great Britain; May 2nd, 2008: Integrating Genomics into Children’s Oncology Group (COG) ALL Trials
102. American Society of Pediatric Hematology/Oncology Preconference Symposium Children’s Oncology Group acute lymphoblastic leukemia trial strategy: past, present and future; Cincinnati, OH; May 14th, 2008: Modern COG ALL therapy: Where did it come from? Where is it going?
103. Pediatric Hematology/Oncology Research Conference, Texas Children’s Cancer Center and Baylor University School of Medicine; Houston, Texas; May 23rd, 2008; Childhood acute lymphoblastic leukemia: Challenges for the next decade
104. American Society of Hematology Clinical Research Training Institute, Dana Point, CA; August 7th, 2008: Conducting Clinical Research Within Cooperative Groups
105. Grand Rounds, Poudre Valley Hospital, Fort Collins, CO; August 19th, 2008; Treatment of cancer in adolescents and young adults
106. Grand Rounds, Avista Adventist Hospital, Louisville, CO; August 20th, 2008; Childhood leukemia: What happens after an abnormal CBC
107. International Society of Pediatric Oncology (SIOP) Annual Meeting; Free Paper Session ALL2 Biology and Outcome; Berlin, Germany; October 4th, 2008; Improved survival for children with acute lymphoblastic leukemia (ALL) from 1990-2005: A report from the Children’s Oncology Group.
108. International Society of Pediatric Oncology (SIOP) Annual Meeting Plenary Session; Berlin, Germany; October 4th, 2008; Intramural and extramural NCI collaboration: The childhood ALL TARGET project.
109. International Society of Pediatric Oncology (SIOP) Annual Meeting; Berlin, Germany; October 4th, 2008; Chair for Free Paper Session Leukemia and Stem Cell Transplantation.
110. Pediatric Oncology Group of Ontario Multi-disciplinary Symposium on Childhood Cancer; Toronto, Ontario, Canada; November 21st, 2008; Targeted therapy in ALL: The evolving story
111. Pediatric Oncology Group of Ontario Multi-disciplinary Symposium on Childhood Cancer; Toronto, Ontario, Canada; November 22nd, 2008; Meet the Expert Breakfast Session
112. Chairman, American Society of Hematology Education Session; American Society of Hematology Annual Meeting; San Francisco, CA; December 6th, 2008; Junior-Faculty Development: How to Get a Grant
113. American Society of Hematology Annual Meeting; San Francisco, CA; December 8th, 2008. Career Development Lunch Speaker
114. Video Continuing Medical Education Conference, Robert Michael Educational Institute (); San Francisco, CA: December 4th, 2008; Expert Insights in Acute Lymphoblastic Leukemia: Current Challenges and Future Directions
115. American Society of Pediatric Hematology/Oncology Board Review Course; Dallas, TX; February 7th, 2009; Acute Lymphoblastic Leukemia
116. BMT Tandem Meetings; Tampa, FL; February 7th, 2009; The Role of Hematopoietic Stem Cell Transplantation (HSCT) for Acute Leukemia in Infants
117. Children’s Oncology Group Cytogenetics Committee Meeting on The Cytogenetics of Pediatric Leukemia; St. Louis, MO; February 13th, 2009; COG Acute Lymphoblastic Leukemia Studies: Updates
118. XIIth Congress of the Association of Central American Pediatric Hematologists and Oncologists (AHOPCA); San Jose, Costa Rica; February 22nd, 2009; COG Treatment of Standard Risk ALL: Implications for Therapy in Lower Income Countries
119. Board of Scientific Advisors Meeting, National Cancer Institute; Bethesda, MD; March 3rd, 2009; COG ALL TARGET Project: Identification of JAK as a Therapeutic Target
120. CME Conference on Acute Leukemia in Adolescents and Young Adults; Denver, CO; April 9th, 2009; High Risk Acute Lymphoblastic Leukemia in Children, Adolescents and Young Adults
121. The Colorado Association of Family Physicians Annual Scientific Conference; Cheyenne Mountain Resort, Colorado Springs, CO; April 17th, 2009; Treatment of cancer in adolescents and young adults
122. Tenth Annual International Childhood Acute Lymphoblastic Leukemia Ponte di Legno Working Group Meeting; Ponte di Legno, Italy; May 7th 2009; Clinical trials of biologically targeted agents in ALL: From BCR-ABL to JAK and beyond
123. Twentieth Annual International BFM Study Group Meeting; Bergamo, Italy; May 8th 2009; COG acute lymphoblastic leukemia trials 2009: Ongoing studies and new initiatives
124. Twentieth Annual International BFM Study Group Meeting; Bergamo, Italy; May 9th 2009; High throughput genomic studies in ALL: Identification of new therapeutic targets
125. Twentieth Annual International BFM Study Group Meeting; Bergamo, Italy; May 9th 2009; Plenary Session Roundtable Discussion: What do clinicians and biologists expect from molecular and genomic research?
126. Robert Reid Cabral Hospital, Santo Domingo, Dominican Republic; June 4th, 2009; Development of modern therapy for childhood acute lymphoblastic leukemia
127. American Society of Hematology Clinical Research Training Institute, La Jolla, CA; August 4th, 2009: Breakout session: Setting up a new disease program at a small University
128. American Society of Hematology Clinical Research Training Institute, La Jolla, CA; August 6th, 2009: Conducting Clinical Research Within Cooperative Groups
129. American Society of Hematology Clinical Research Training Institute, La Jolla, CA; August 6th, 2009: Breakout session: Strategies to get involved in Cooperative Groups or National Organizations
130. International Society of Paediatric Oncology 41st Congress, Sao Paulo, Brazil; October 7th and 8th, 2009; Meet the Experts Session (with Andrea Biondi): Management of Philadelphia Chromosome Positive (Ph+) ALL
131. International Society of Paediatric Oncology 41st Congress Sao Paulo, Brazil; October 7th, 2009; Abstract Awards Session: The Spectrum Of Mutations In Childhood ALL (Winner of SIOP Award for Basic Science)
132. International Society of Paediatric Oncology 41st Congress; Sao Paulo, Brazil; October 7th, 2009; Plenary Session: Genomic Approaches To Molecular Target Identification and Validation: Experience In Childhood ALL
133. American Society of Hematology Trainees Day; New Orleans, LA; December 4th, 2009; How to Mange a Clinical Research Team
134. National Cancer Institute Meeting on Adolescent and Young Adult Acute Lymphoblastic Leukemia; New Orleans, LA; December 4th, 2009; Children’s Oncology Group Young Adult ALL Results and Efforts
135. COG/EsPhALL Meeting; New Orleans, LA; December 6th, 2009; Treatment of Philadelphia chromosome positive ALL in the Children’s Oncology Group and Proposal for a Transatlantic COG-EsPhALL Ph+ ALL Trial
136. Unidad Nacional de Oncologica Pediatrica de Guatemala; Guatemala City, Guatemala; January 11th, 2010; COG Treatment of Standard Risk ALL: Implications for Therapy in Lower Income Countries
137. University of Colorado Cancer Center Grand Rounds; University of Colorado School of Medicine; Aurora, CO; January 19th, 2010; Genomic Approaches to Molecular Target Identification and Development of Targeted Therapy in Pediatric Acute Lymphoblastic Leukemia
138. Fourth St. Jude-VIVA Forum on Hematological Malignancies in Children; Singapore; March 3rd, 2010; Target Identification and Targeted Therapy for ALL – Imatinib and Beyond
139. Fourth St. Jude-VIVA Forum on Hematological Malignancies in Children; Singapore; March 3rd, 2010; Meet the Expert Lunch Session: Induction and consolidation therapy for ALL in developing regions
140. American Society of Pediatric Hematology/Oncology Annual Meeting Symposium: Preconference Symposium: Improving Outcomes For High Risk All - Translating New Discoveries Into Clinical Care; Montreal, Canada; April 9th, 2010: Overview on The Pathway From Identification of Lesions That can be Targeted to Clinical Trials Development Using Ph+ ALL As A Paradigm
141. University of Colorado Grand Rounds in Clinical Genetics and Metabolism; University of Colorado School of Medicine; Aurora, CO; May 26th, 2010; The Genetics of Pediatric Cancer
142. American Society of Clinical Oncology Annual Meeting, Chicago, IL; June 6th, 2010; Education Session Chair: Optimal Treatment for Adolescents and Young Adults with Acute Lymphoblastic Leukemia
143. American Society of Clinical Oncology Annual Meeting, Chicago, IL; June 6th, 2010; Education Session: Converging Approaches to Treating Childhood, Adolescent, and Young Adult ALL
144. American Society of Clinical Oncology Annual Meeting, Chicago, IL; June 6th, 2010; Pediatric Oncology Poster Discussant: Next Generation Biomarkers in Leukemia
145. Children’s Mercy Hospital Visiting Professor Lecture, Kansas City, MO; June 14th, 2010; Modern COG ALL Therapy: Where Did It Come From and Where Is It Going?
146. American Society of Hematology Clinical Research Training Institute, La Jolla, CA; August 3rd, 2010: What We Look for When We Hire (with Marilyn Telen)
147. American Society of Hematology Clinical Research Training Institute, La Jolla, CA; August 5th, 2010: Conducting Clinical Research Within Cooperative Groups (with John Leonard)
148. American Society of Hematology Clinical Research Training Institute, La Jolla, CA; August 5th, 2010: Career Introspection
149. Twenty-first Annual International BFM Study Group Meeting; Antalya, Turkey; October 2nd, 2010; COG acute lymphoblastic leukemia study updates and plans for future trials
150. Twenty-first Annual International BFM Study Group Meeting; Antalya, Turkey; October 2nd, 2010; COG ALL TARGET Project and Development of JAK Inhibitor Therapy for ALL
151. 7th Bi-annual Symposium on Childhood Leukemia; Antalya, Turkey; October 4th, 2010; COG Approaches to Refractory Acute Lymphoblastic Leukemia
152. 7th Bi-annual Symposium on Childhood Leukemia; Antalya, Turkey; October 4th, 2010; Session Chair and Moderator: Novel Treatments for Refractory Acute Lymphoblastic Leukemia
153. Eleventh Annual International Childhood Acute Lymphoblastic Leukemia Ponte di Legno Working Group Meeting; Newport, Rhode Island; October 19th 2010; Development of an International Trial for Ph+ ALL: Implications for other High Risk ALL Subsets
154. Eleventh Annual International Childhood Acute Lymphoblastic Leukemia Ponte di Legno Working Group Meeting; Newport, Rhode Island; October 20th 2010; Session Chair and Moderator New Molecular Genetic Subtypes of ALL
155. International Society of Paediatric Oncology 42nd Congress, Boston, MA; October 21st, 2010; State of the Art Event on Acute Lymphoblastic Leukemia: Treatment of Philadelphia Chromosome Positive ALL: The Role of Tyrosine Kinase Inhibitor Therapy
156. International Society of Paediatric Oncology 42nd Congress, Boston, MA; October 21st, 2010; State of the Art Event on Acute Lymphoblastic Leukemia: New Insights In Genetics of Acute Lymphoblastic Leukemia
157. International Society of Paediatric Oncology 42nd Congress, Boston, MA; October 22nd, 2010; Session Chair and Moderator: Free Papers Session #7 Acute Lymphoblastic Leukemia
158. Grand Rounds, the Department of Pediatrics; The Children’s Hospital, Aurora, CO; November 5th, 2010; Identification of New Therapeutic Targets in Childhood Acute Lymphoblastic Leukemia with High Throughput Genomics and Next Generation Sequencing
159. American Society of Hematology Annual Meeting; Orlando; FL; December 4th, 2010; Junior Faculty Development; Show Me the Money: Negotiating Your Salary and Benefits
160. American Society of Hematology Annual Meeting; Orlando, CA; December 6th, 2010; Co-Chairman for Simultaneous Session Leukemias – Biology, Cytogenetics and Molecular Markers in Diagnosis and Prognosis: Impact of Biological Factors on Prognosis in Childhood ALL
161. NCI TARGET Steering Committee Meeting; Bethesda, MD; December 17th, 2010: Update on acute lymphoblastic leukemia TARGET Project
162. American Society of Pediatric Hematology/Oncology Board Review Course; Dallas, TX; February 12th, 2011; Acute Lymphoblastic Leukemia
163. American Association for Cancer Research Annual Meeting; Orlando, CA; April 3rd, 2011; Co-Chairman and Organizer of New Concepts in Organ Site Research Session; Pediatric Acute Lymphoblastic Leukemia: Genomics, FISH, and Cell Death
164. American Association for Cancer Research Annual Meeting; Orlando, CA; April 3rd, 2011; Pediatric Acute Lymphoblastic Leukemia: Genomics, FISH, and Cell Death New Concepts in Organ Site Research Session; Discoveries from the TARGET high-risk childhood ALL project
165. American Association for Cancer Research Annual Meeting; Orlando, CA; April 6th, 2011; The NCI Therapeutically Applicable Research to Generate Effective Treatments (TARGET) Initiative: Using Large-Scale Genomics to Identify Novel Therapeutic Targets for Childhood Cancers Session; Acute lymphoblastic leukemia
166. Rocky Mountain Blood Cancer Conference 2011; Aurora, CO; April 9th, 2011; Pediatric Leukemias and Lymphomas
167. American Society of Pediatric Hematology Oncology Annual Meeting; Baltimore, MD; April 14th, 2011; Meet the Expert Lunch Session: Clinical Research in Pediatric Oncology
168. Department of Pediatrics Grand Rounds, Memorial Sloan Kettering Cancer Center; New York City, NY; April 21st, 2011; Pediatric Acute Lymphoblastic Leukemia: Advances in Treatment and Identification of New Therapeutic Targets
169. Sixth International Congress of the Dominican Society of Hematology; Caso de Campo, La Romana, Republica Dominica; April 30th, 2011; Improving ALL Outcomes In the United States and in the Dominican Republic
170. Children’s Hospital of Philadelphia; Philadelphia, PA; May 3rd, 2011; Pediatric Acute Lymphoblastic Leukemia: Advances in Treatment and Identification of New Therapeutic Targets
171. Twenty-second Annual International BFM Study Group Meeting; Gdansk, Poland; May 6th, 2011; COG Acute Lymphoblastic Leukemia trials 2011: Updates and Plans for Future Trials
172. Twenty-second Annual International BFM Study Group Meeting; Gdansk, Poland; May 7th, 2011; Slow-responding and Refractory T-ALL: COG Definitions and Strategies
173. Twenty-second Annual International BFM Study Group Meeting; Gdansk, Poland; May 7th, 2011; Treatment of Philadelphia Chromosome Positive (Ph+) ALL: Development of a Joint COG-EsPhALL Trial
174. Twenty-second Annual International BFM Study Group Meeting; Gdansk, Poland; May 7th, 2011; Results of COG AALL0232 B-cell Precursor ALL Trial
175. Twenty-second Annual International BFM Study Group Meeting; Gdansk, Poland; May 7th, 2011; Prognostic Significance of IKZF1 and CRLF2 Alterations in COG ALL Trials
176. American Society of Clinical Oncology Annual Meeting; Chicago, IL; June 6th, 2011; Meet the Professor Session: Update on the Treatment of Adolescents and Young Adults with Acute Lymphocytic Leukemia
177. American Cancer Society Cancer Action Network Colorado Research Breakfast; Denver, CO; July 20th, 2011; Advances in the Cure of Childhood Acute Lymphoblastic Leukemia
Presentations: Local and Other (2008-present)
1. University of Colorado Cancer Center External Advisory Board Meeting; Aurora, CO; February 6th, 2008; Pediatric Oncology Program at The Children’s Hospital
2. Sunshine Project Annual Meeting; Tampa, FL; March 14th, 2008; Update on Clinical Trials
3. Children’s Oncology Group Spring Meeting; Los Angeles, CA; April 2nd, 2008; COG ALL Committee Structure, Meeting Goals, Timelines for Current and New Trials
4. Pediatric Oncology Experimental Therapeutics Investigators Consortium (POETIC) Summer Meeting; Banff, Alberta, Canada; July 20th, 2008; Sunshine Project Clinical Trials: Status
5. Center for Cancer and Blood Disorders Quality Improvement Meeting; The Children’s Hospital, Aurora, CO; August 13th, 2008; Medication Errors
6. Pediatric Hematology/Oncology Fellows Teaching Conference; The Children’s Hospital, Aurora, CO; August 15th, 2008; Modern COG ALL Therapy Past, Present and Future
7. Channel 9 News Interview; Denver, CO; August 20th, 2008; Pediatric Cancer
8. Center for Cancer and Blood Disorders Professor’s Rounds; The Children’s Hospital, Aurora, CO; September 12th, 2008; Modern COG ALL Therapy: Where Did It Come From? Where Is It Going?
9. Center for Cancer and Blood Disorders Annual Research Retreat; Aspen, CO; September 16th, 2008; Genomics in COG ALL Trials
10. Children’s Oncology Group Fall Meeting ALL Biology Session; Denver, CO; October 22nd, 2008; Update on the COG High Risk ALL TARGET Project and Development of New Genomic-Based Assays to Identify High-Risk Patients
11. Children’s Oncology Group Fall Meeting ALL Frontline Trials Session; Denver, CO; October 22nd, 2008; COG ALL Committee Updates
12. Children’s Oncology Group Fall Meeting Stem Cell Transplant for ALL in First Remission Breakout; Denver, CO; October 22nd, 2008; The Potential Role of Stem Cell Transplant for ALL in First Remission
13. Children’s Oncology Group Fall Meeting Translational Research Committee Meeting; Denver, CO; October 23rd, 2008; TARGET High Risk ALL Pilot Project
14. Children’s Oncology Group Fall Meeting Development Therapeutics Meeting; Denver, CO; October 23rd, 2008; Panel Member and Discussant: Development of Targeted Therapies
15. Pediatric Hematology/Oncology Fellows Teaching Conference; The Children’s Hospital, Aurora, CO; November 25th, 2008; How to Look for a “Real Job”
16. Children’s Oncology Group Spring Meeting; ALL Committee Steering Committee; Dallas, TX; March 11th, 2009; COG ALL Committee Updates
17. Children’s Oncology Group Spring Meeting; Group Update—Breaking News; Dallas, TX; March 11th, 2009; Discovery of JAK as a Therapeutic Target in High-Risk ALL
18. Pediatric Hematology/Oncology Fellows Teaching Conference; The Children’s Hospital, Aurora, CO; August 14th, 2009; Modern COG ALL Therapy Past, Present and Future
19. Center for Cancer and Blood Disorders Annual Research Retreat; Aspen, CO; September 16th, 2009; Identification of Recurrent Genomic Lesions and Development of Targeted Therapies in Childhood ALL
20. Research Strategic Plan External Advisory Committee; The Children’s Hospital, Aurora, CO; September 21st, 2009; Report of the Areas of Research Emphasis/Themes/Timing Committee
21. Children’s Oncology Group Fall Meeting Acute Lymphoblastic Leukemia Committee Breakout Session on Infectious Issues in ALL; Dallas, TX; September 30th, 2009; Non-Relapse Mortality in ALL: The Clinical Problem
22. Children’s Oncology Group Fall Meeting Acute Lymphoblastic Leukemia Committee Breakout Session on Development of Molecularly Targeted Therapies; Dallas, TX; September 30th, 2009; Major unanswered questions in Ph+ ALL and opportunities for international collaboration
23. Children’s Oncology Group Fall Meeting Acute Lymphoblastic Leukemia Committee Open Session; Dallas, TX; September 30th, 2009; Updates on Clinical Trials and Research Findings
24. Children’s Oncology Group Fall Meeting Translational Research Committee Meeting; Dallas, TX; October 1st, 2009; The Children’s Oncology Group High-Risk ALL TARGET Pilot Project and Expansion
25. Children’s Oncology Group Fall Meeting Clinical Research Associates Meeting; Dallas, TX; October 1st, 2009; COG ALL Committee Update for Clinical Research Associates
26. Pediatric Hematology/Oncology Research in Progress; The Children’s Hospital, Aurora, CO; October 28th, 2009; Identification of Recurrent Genomic Lesions and Development of Targeted Therapies in Childhood ALL
27. Pediatric Hematology/Oncology Fellows Teaching Conference; The Children’s Hospital, Aurora, CO; November 24th, 2009; How to Look for a “Real Job”
28. Pediatric Hematology/Oncology Fellows Teaching Conference; The Children’s Hospital, Aurora, CO; March 16th, 2010; Non-Hodgkin Lymphoma
29. Children’s Oncology Group Spring Meeting Acute Lymphoblastic Leukemia Committee Breakout Session on Development of an International Randomized Trial for Philadelphia Chromosome Positive ALL; Los Angeles, CA; March 24th, 2010; Update on Outcomes for Ph+ ALL in the pre-Imatinib Era
30. Children’s Oncology Group Spring Meeting Acute Lymphoblastic Leukemia Committee Breakout Session on Development of an International Randomized Trial for Philadelphia Chromosome Positive ALL; Los Angeles, CA; March 24th, 2010; Update on Discussions with EsPhALL and Status of Proposed Joint Trial
31. Children’s Oncology Group Spring Meeting Acute Lymphoblastic Leukemia Steering Committee; Los Angeles, CA; March 25th, 2010; Updates on Clinical Trials and Research Findings and Future Plans
32. Pediatric Hematology/Oncology Fellows Teaching Conference; The Children’s Hospital, Aurora, CO; August 27th, 2010; Modern COG ALL Therapy: Where Did It Come From and Where Is It Going?
33. Children’s Oncology Group Fall Meeting Acute Lymphoblastic Leukemia Committee Open Session; Dallas, TX; September 22nd, 2010; Updates on Clinical Trials and Research Findings
34. Children’s Oncology Group Fall Meeting Clinical Research Associates Meeting; Dallas, TX; September 22nd, 2010; COG ALL Committee Update for Clinical Research Associates
35. Children’s Oncology Group Fall Meeting Acute Lymphoblastic Leukemia Committee Breakout Session on Development of JAK Inhibitor Therapy; Dallas, TX; September 23rd, 2010; Overview and review of JAK mutations in ALL
36. Pediatric Hematology/Oncology Research in Progress; The Children’s Hospital, Aurora, CO; October 28th, 2009; Improving Outcome for Childhood ALL: A Tale of Two Countries
37. Children’s Oncology Group Spring Meeting Acute Lymphoblastic Leukemia Committee Session; Los Angeles, CA; March 23rd, 2011; Updates on Clinical Trials and Research Findings
................
................
In order to avoid copyright disputes, this page is only a partial summary.
To fulfill the demand for quickly locating and searching documents.
It is intelligent file search solution for home and business.
Related searches
- curriculum vitae template word document
- curriculum vitae finance manager sample
- curriculum vitae format in word
- curriculum vitae sample doc
- curriculum vitae sample pdf
- curriculum vitae samples for teachers
- curriculum vitae template free download
- curriculum vitae template word download
- nursing curriculum vitae template pdf
- best curriculum vitae format
- curriculum vitae en francais modele
- curriculum vitae examples word